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In Brief
Transforming growth factor b (TGF-b)
leads to the phosphorylation of Smad
proteins and thereby facilitates the
formation of different trimeric Smad
complexes. By combining quantitative
mass spectrometry with mathematical
modeling, the identities of the formed
trimeric Smad complexes are resolved
and the link of these transcription factors
with target gene expression is
established. This approach allows
predicting based on gene expression
data that in hepatocellular carcinoma the
abundance of Smad proteins and their
phosphorylation is elevated, which was
experimentally validated..
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Upon stimulation of cells with transforming growth
factor b (TGF-b), Smad proteins form trimeric com-
plexes and activate a broad spectrum of target genes.
It remains unresolved which of the possible Smad
complexes are formed in cellular contexts and how
these contribute to gene expression. By combining
quantitative mass spectrometry with a computational
selection strategy, we predict and provide experi-
mental evidence for the three most relevant Smad
complexes in the mouse hepatoma cell line Hepa1-6.
Utilizing dynamic pathway modeling, we specify the
contribution of each Smad complex to the expression
of representative Smad target genes, and show that
thesecontributionsareconserved inhumanhepatoma
cell lines and primary hepatocytes. We predict, based
ongeneexpressiondataofpatient samples, increased
amounts of Smad2/3/4 proteins and Smad2 phos-
phorylation as hallmarks of hepatocellular carcinoma
and experimentally verify this prediction. Our findings
demonstrate that modeling approaches can disen-
tangle the complexity of transcription factor complex
formation and its impact on gene expression.
INTRODUCTION
Transforming growth factor b (TGF-b) is a pleiotropic factor with
multiple functions for which the underlying mechanisms are onlyCell Systems 6, 1–15,
This is an open access article under the CC BY-Npartially understood. The most prominent intracellular mediators
of TGF-b signaling are the Smad proteins. The receptor Smad
proteins, Smad2 and Smad3, interact with the common Smad
(Smad4), form trimeric complexes, and translocate to the nu-
cleus, where they interact with other proteins including other
transcription factors and regulate transcription of hundreds of
genes (Moustakas and Heldin, 2002). Smad2 and Smad3 are
regulated by phosphorylation, but not Smad4. Based on the
three Smad proteins with three phosphorylation states for
Smad2 and Smad3 (n = 7) and the trimeric complexes (k = 3),
the theoretical number of different Smad complexes can be
calculated according to the formula for unordered sampling
with replacement:

n+ k  1
k

= 84 (Equation 1)
Thus, in principle, 84 different trimeric Smad complexes can
form, but it has not been determined which Smad complexes
indeed occur in particular cell types such as hepatocytes.
Depending on the cell type, only distinct sets of target genes
are induced by TGF-b. This could be mediated by the interaction
of Smad complexes with other transcription factors or crosstalk
with other signaling pathways (Feng and Derynck, 2005). In addi-
tion, the amount, composition, or dynamics of Smad complex
formation could differ. Therefore, systematic studies are
required to decipher the contribution of individual Smad com-
plexes to gene expression.
Numerous intragenic mutations and homozygous deletions of
Smad2 and Smad4, as well as downregulation of Smad3 mRNA,
were reported for different forms of carcinoma (Levy and Hill,
2006). While attempts were made to quantify Smad expressionJanuary 24, 2018 ª 2017 The Authors. Published by Elsevier Inc. 1
C-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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dance of Smad proteins in liver cancer tissue and hepatoma
cell lines compared with primary hepatocytes have not been
addressed. So far the impact of TGF-b stimulation was only
examined in proteome-wide studies that analyzed changes in
proteins and phosphorylation sites (Ali and Molloy, 2011;
D’Souza et al., 2014). However, comprehensive information on
the abundance and the degree of phosphorylation of Smad pro-
teins is currently not available.
TGF-b-induced signal transduction has been approached by
mathematical modeling that addressed the dynamics of ligand-
receptor interaction, identified the role of negative feedbacks,
and provided insights into nuclear-cytoplasmic shuttling (Schmi-
erer et al., 2008; Zi et al., 2011). However, most of these mathe-
matical models were primarily based on literature knowledge,
and only few of these studies included experimental data.
None of the previously published mathematical models ac-
counted for the composition of the trimeric Smad complexes
and the specific link to Smad complex-mediated gene
expression.
Combining mass spectrometric data and mathematical
modeling as utilized for the analysis of mechanisms governing
dimerization of phosphorylated Stat5 (Boehm et al., 2014), could
provide valuable information on Smad complex formation. In
such an approach, proteomics provides data on protein abun-
dance, while mathematical modeling provides a tool for an unbi-
ased selection strategy for the identification of transcription
factor complexes that are present in a given cell type. Since
the number of candidate models grows exponentially with the
number of model parameters, finding the exact solution of
such a model selection task is very challenging. We developed
a method to distinguish non-essential from essential model
parameters by combining nonlinear mathematical modeling
with L1 regularization (Merkle et al., 2016; Steiert et al., 2016).
The L1 regularization approach can be employed to investigate
which model reactions are required to describe experimental
data. Therefore the L1 regularization approach could be utilized
to statistically assess which individual reaction parameters lead-
ing to complex formation are necessary and sufficient and
thereby identify essential protein complexes.
Here we combine quantitative experimental techniques with
mathematical modeling approaches to resolve complexity in
Smad complex formation and to establish a quantitative link to
transcriptional activities in hepatoma cell lines and primary
hepatocytes.
RESULTS
Abundance and Interactions of Smad Proteins
To examine the TGF-b-induced formation of Smad complexes,
we quantified the amount of Smad proteins in unstimulated
Hepa1-6 cells using antibodies that specifically recognize
Smad2, Smad3, or Smad4 as well as an antibody with equal
affinity to Smad2 and Smad3 (Figure S1A). Immunoprecipitation
(IP) and quantitative immunoblotting (IB) experiments in combi-
nation with recombinant proteins (Figure S1B) revealed
825,000 ± 74,000 Smad2 and 402,000 ± 113,000 Smad4 mole-
cules per cell in Hepa1-6 cells (Figure 1A). To define the relative
abundance of Smad2 and Smad3, we combined isoform-inde-2 Cell Systems 6, 1–15, January 24, 2018pendent Smad2/3 IP with quantitative mass spectrometry
(Boehm et al., 2014). The results revealed a ratio of approxi-
mately 10:1 between Smad2 and Smad3 that was unaffected
by TGF-b treatment, with a total amount of 83,000 ± 6,600
Smad3 molecules per Hepa1-6 cell (Figure 1B).
To analyze the dynamics of TGF-b-induced phosphorylation of
Smad2 and Smad3 in Hepa1-6 cells, we stimulated cells with
1 ng/mL TGF-b for up to 10 hr and performed IP experiments
followed by mass spectrometry. These measurements enabled
us to distinguish non-phosphorylated Smad2 and Smad3
(nSmad2 and nSmad3), Smad2 and Smad3 phosphorylated at
the most C-terminal serine residue (pSmad2 at Ser467; pSmad3
at Ser425), and Smad2 and Smad3 phosphorylated at the two
most C-terminal serine residues (ppSmad2 at Ser465 and
Ser467; ppSmad3 at Ser423 and Ser425). At t = 0 min almost
all Smad2 and Smad3molecules were non-phosphorylated (Fig-
ure 1C). Upon TGF-b stimulation, the amount of nSmad2
decreased until 60 min and increased at later time points.
60 min after TGF-b stimulation, 5% of total Smad2 was present
as pSmad2. The abundance of ppSmad2 rapidly increased, with
a peak at 60 min after TGF-b stimulation at which the amount
corresponded to 60% of total Smad2, followed by a decrease
to basal levels after 10 hr. Similar dynamics were observed for
nSmad3, pSmad3, and ppSmad3.
To determine to which extent Smad2 and Smad3 engage
in complex formation, Hepa1-6 cells were stimulated with
1 ng/mL TGF-b for 60 min. The total amount of Smad2 and
Smad3, their phosphorylation status, and the amount of the
co-immunoprecipitated Smad2, Smad3, and Smad4 were
quantified by mass spectrometry (Figure 1D). Only doubly
phosphorylated Smad3 co-immunoprecipitated with Smad2
(Figure 1D, left panel) and the amount of co-immunoprecipi-
tated Smad3 (28,000 ppSmad3 molecules/cell) was low
compared with the amount of Smad2 (825,000 molecules/
cell). Only ppSmad2 was co-immunoprecipitated with
Smad3 (Figure 1D, right panel). Out of 550,000 ppSmad2
molecules per Hepa1-6 cell, only about 4% formed a complex
with Smad3. In Smad2 and Smad3 IPs, we could detect co-
immunoprecipitation (coIP) of Smad4. The Smad4 amount
detected after Smad2 IP was approximately 35-fold higher
than after Smad3 IP (69,000 and 2,000 molecules/cell, respec-
tively), suggesting a higher abundance of formed Smad2:
Smad4 complexes compared with Smad3:Smad4 interac-
tions. These results revealed that only doubly phosphorylated
Smad2 and Smad3 molecules formed complexes. Despite the
high degree of Smad2 and Smad3 phosphorylation, only few
Smad2 molecules interacted with Smad3. On the other hand,
around 30% of all Smad3 molecules are associated with
Smad2 upon stimulation with TGF-b. We also examined the
Smad complex formation in a time- and TGF-b dose-depen-
dent manner in Hepa1-6 cells (Figures S1C and S1D). We
concluded that the efficacy of Smad complex formation may
be highly dependent on the molecular ratio of the individual
Smad proteins.
Identification of the Most Relevant Smad Complexes
Theoretically, a large number of trimeric Smad2, Smad3, and
Smad4 complexes with different composition could be formed.
Trimeric complexes (k = 3) with nSmad2, pSmad2, ppSmad2,
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Figure 1. Abundance and Dynamics of TGF-b-Induced Smad Pathway Components
(A) Abundance of Smad2 and Smad4 proteins in Hepa1-6 cells determined by quantitative immunoblotting (IB). Error bars represent SEM (n = 18).
(B) Hepa1-6 cells were stimulated with 1 ng/mL TGF-b and relative protein abundance of Smad2 to Smad3 was determined by mass spectrometry (n = 2).
(C) Whole-cell lysates of Hepa1-6 cells stimulated with 1 ng/mL TGF-b were subjected to IP with anti-Smad2/3 antibodies (n = 3 for Smad2 and n = 2 for Smad3)
and analyzed by mass spectrometry for absolute phosphorylation levels of Smad2 and Smad3. n, non-phosphorylated; p, singly phosphorylated; pp, doubly
phosphorylated. Error bars represent 5% error from mass spectrometry measurement.
(D) Whole-cell lysates of Hepa1-6 cells stimulated with 1 ng/mL TGF-b for 60 min were used for IP with anti-Smad2 or anti-Smad3 antibodies. Amounts of coIP
nSmad2/3, pSmad2/3, ppSmad2/3, and Smad4 are shown. Smad2, Smad3, and Smad4 protein abundance was determined by mass spectrometry (n = 3 for
Smad2 and n = 2 for Smad3 and Smad4). Error bars represent 5% error from mass spectrometry measurement.
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84 possible complexes based on Equation 1. Since only
ppSmad2, ppSmad3, and Smad4 substantially engage in com-
plex formation (n = 3), this number is reduced to 10. As we
observed major differences in the total amount of Smad2 and
Smad3 proteins, it is possible that only a much smaller number
of Smad complexes occurs in Hepa1-6 cells.
To disentangle the combinatorial complexity of Smad
complex formation, we combined quantitative experiments
with mathematical modeling. The established mathematical
model consists of 31 mass-action kinetic reactions and 16
dynamical parameters that describe TGF-b receptor activa-
tion and Smad complex formation (Figure 2A). In the model,
the formation of each of the ten possible trimeric Smad com-
plexes consisting of ppSmad2, ppSmad3, and Smad4 was
characterized by a complex-specific association rate (kon).
The dissociation of each trimeric Smad complex was depen-
dent on the dephosphorylation of ppSmad2 and ppSmad3 in
the heterotrimeric Smad complexes or on the dissociation of
the homotrimeric Smad4 complex (Figure 2A). The mathemat-
ical model with ten complexes was capable of describing thetime and dose dependency of Smad complex formation
(Figure S1E).
To identify the most relevant Smad complexes in Hepa1-6
cells, we employed a data-based model selection approach
(Merkle et al., 2016; Steiert et al., 2016) to eliminate complexes
not required to explain the experimental data. For this purpose,
we added an L1 regularization term to the kon parameters favor-
ing a minimal number of distinct complexes in the mathematical
model. For statistical assessment, we calculated the profile like-
lihoods for the ten kon parameters of the considered trimeric
Smad complexes (Raue et al., 2009), indicating the parameter
ranges that are compatible with the experimental data. For seven
of the ten kon parameters (Figure 2B), the best parameter estima-
tion value (red asterisk) was compatible with 1014, which is
equivalent to zero. For the other three kon parameters, the best
parameter estimation value was significantly different from
zero. These results suggested that only three complexes
ppSmad2:ppSmad3:ppSmad3, ppSmad2:Smad4:Smad4, and
ppSmad2:ppSmad3:Smad4 are necessary to describe the
experimental data. The reduced mathematical model
comprising only these three Smad complexes (Figure 2C) wasCell Systems 6, 1–15, January 24, 2018 3
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Figure 2. Data-Driven Model Reduction Identifies Relevant Smad Complexes
(A) A mathematical model describes the formation of ten different homo- and heterotrimers comprising ppSmad2, ppSmad3, and Smad4.
(B) Employment of model reduction by L1 regularization to identify the relevant Smad complexes required to explain the experimental data. The black curves
indicate the profile likelihood for the association rate (kon) of a specific complex. For three complexes (gray background) the profile likelihood, 2 log(PL), in-
creases above the statistical threshold (red dashed line) if the association rate is deviating from the estimated value (red asterisk).
(C) Structure of the reduced model.
(D) Description of the experimental data by the reduced model. Left panels: Smad2 (n = 1), Smad3 (n = 2), and Smad4 (n = 2). Right panels: Smad2 (n = 2), Smad3
(n = 1), Smad4 (n = 1), and Smad2/3 (n = 2). Dots, experimental mass spectrometric data; continuous line, model trajectories; shading, 5% error.
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Expression, Cell Systems (2017), https://doi.org/10.1016/j.cels.2017.11.010able to describe the experimental data (Figure 2D) to a similar
extent as the comprehensive mathematical model considering
all ten possible trimeric Smad complexes. The goodness-of-fit
of the reduced model was assessed by the chi-square statistics
c2 = Si((yi–fi)/si)
2, which increases by 0.71 after removing seven4 Cell Systems 6, 1–15, January 24, 2018complexes from 743.56 to 744.28 for 342 data points, supporting
the model reduction. Thus, the model proposes ppSmad2:
ppSmad3:ppSmad3, ppSmad2:Smad4:Smad4, and ppSmad2:
ppSmad3:Smad4 as the most relevant TGF-b-induced Smad
complexes in Hepa1-6 cells.
Smad2
Smad3
Smad3
Smad2
Smad4
Smad4
Smad2
Smad3
Smad4
target gene
P P
P P
P P
P P P P
P P
D F
time (min) time (min) time (min)
ge
ne
 e
xp
re
ss
io
n 
(lo
g 2
)
ge
ne
 e
xp
re
ss
io
n 
(lo
g 2
)
ge
ne
 e
xp
re
ss
io
n 
(lo
g 2
)
ge
ne
 e
xp
re
ss
io
n 
(lo
g 2
)
−1.5
−1
−0.5
0
0.5
−1
−0.5
0
0.5
−2
−1.5
−1
−0.5
0
0.5
Cluster 10 Cluster 11 Cluster 12
0
1
2
3
−0.5
0
0.5
1
1.5
2
2.5
−2
−1
−1.5
−0.5
0
Cluster 7 Cluster 8 Cluster 9
−0.5
0
0.5
1
1.5
2
2.5
3
−0.5
0
0.5
1
1.5
2
2.5
0
1
2
3
Cluster 4 Cluster 5 Cluster 6
−0.5
0
0.5
1
1.5
2
2.5
3
−0.5
0
0.5
1
1.5
2
2.5
−0.5
0
0.5
1
Cluster 1 Cluster 2 Cluster 3
0 120 240 360 480 600 0 120 240 360 480 600
cluster average (untreated)
cluster average (TGFβ-treated)
experimental data (untreated)
experimental data (TGFβ-treated)
0 120 240 360 480 600
0 120 240 360 480 6000 120 240 360 480 600 0 120 240 360 480 600
0 120 240 360 480 600 0 120 240 360 480 600 0 120 240 360 480 600
0 120 240 360 480 600 0 120 240 360 480 600 0 120 240 360 480 600
time (min)
ge
ne
 e
xp
re
ss
io
n 
(lo
g 2
)
ge
ne
 e
xp
re
ss
io
n 
(lo
g 2
)
ge
ne
 e
xp
re
ss
io
n 
(lo
g 2
)
ge
ne
 e
xp
re
ss
io
n 
(lo
g 2
)
−0.4
−0.2
0
0.2
0.4
0.6
Ski (Cluster 1)
0
0.5
1
Skil (Cluster 2)
−0.2
0
0.2
0.4
Dnmt3a (Cluster 3)
0 120 240 360 480 600 0 120 240 360 480 600 0 120 240 360 480 600
0
0.5
1
1.5 Klf10 (Cluster 7)
−0.4
−0.2
0
0.2
0.4
Bmp4 (Cluster 8)
−0.4
−0.2
0
0.2
Cxcl15 (Cluster 9)
−0.5
0
0.5
Sox4 (Cluster 4)
−0.5
0
0.5
1 Jun (Cluster 5)
0
0.5
1
Smad7 (Cluster 6)
0
0.2
-0.2
Dusp5 (Cluster 10)
model trajectories (untreated)
model trajectories (TGFβ-treated)
experimental data (untreated)
experimental data (TGFβ-treated)
0 120 240 360 480 600 0 120 240 360 480 600 0 120 240 360 480 600
0 120 240 360 480 600 0 120 240 360 480 600 0 120 240 360 480 600
0 120 240 360 480 600
time (min)
−0.4
−0.2
0
Pdk4 (Cluster 12)
0 120 240 360 480 600
time (min)
−0.4
−0.2
0
0.2
Tgfa (Cluster 11)
0 120 240 360 480 600
A
Smad2
Smad3
Smad3
P P
P P
P P
Smad4
TGFβ
Smad4 after 
Smad4 depletion
Lysate
0 min 60 min 0 min 60 min 0 min 60 min 0 min 60 min
Smad4-depleted
lysate
Smad2-Smad3
interaction
Smad4-independent
Smad2-Smad3
interaction
Si
gn
al
 in
te
ns
ity
 (a
.u
., 
x1
07
)
TGFβ
Lysate Smad4-depleted
lysate
IP: Smad3; IB: Smad2
TGFβ (min)
Lysate Smad4-depleted lysate
0 60 0 60 0 60 0 600 600 60
IP: Smad4
IB: Smad4 Smad4
IP: Smad3
IB: Smad2 Smad2
IP: Smad3
IB: Smad3
Smad3
3.0
2.0
1.0
0.0
3.0
2.0
1.0
0.0
2.5
1.5
0.5
2.5
1.5
0.5
Si
gn
al
 in
te
ns
ity
 (a
.u
., 
x1
07
)
B
Lysate
0 60 0 60 0 60 0 600 600 60TGFβ (min)
IP: Smad3
IB: Smad3 Smad3
Smad3-depleted lysate
IP: Smad4
IB: Smad2 Smad2
IP: Smad4
IB: Smad4
Smad4
Smad2
Smad4
Smad4
P P
Smad3 Smad3 afterSmad3 depletion
Smad2-Smad4
interaction
Smad3-independent
Smad2-Smad4
interaction
60 min 0 min 60 min 0 min 60 min 0 min 60 minTGFβ
Smad3-depleted
lysate
Lysate Smad3-depleted
lysate
IP: Smad4; IB: Smad2
0 minTGFβ
Lysate
IP: Smad3; IB: Smad3
3.0
2.5
1.5
0.5
2.0
1.0
0.0
3.0
2.0
1.0
0.0
2.5
1.5
0.5
Si
gn
al
 in
te
ns
ity
 (a
.u
., 
x1
07
)
Si
gn
al
 in
te
ns
ity
 (a
.u
., 
x1
07
)
C E
Smad2
Smad3
Smad4
P P
P P
Smad2-Smad3-Smad4
interaction
TGFβ
Sequential IP:
Smad3 and Smad4
IB: Smad2
0 min 60 min
2.0
1.0
3.0
5.0
4.0
0.0Si
gn
al
 in
te
ns
ity
 (a
.u
., 
x1
06
)
Lysate
Sequential IP:
1. IP: Smad3
2. IP: Smad4
0 60 0 60 0 60TGFβ (min)
IB: Smad2
Smad2
Smad4
Smad2
Smad3
IB: Smad2
IB: Smad3
IB: Smad4
Sm
ad
2 I
P
Sm
ad
3 I
P
Sm
ad
4 I
P
Lysate
IP: Smad4; IB: Smad4
(legend on next page)
Cell Systems 6, 1–15, January 24, 2018 5
Please cite this article in press as: Lucarelli et al., Resolving the Combinatorial Complexity of Smad Protein Complex Formation and Its Link to Gene
Expression, Cell Systems (2017), https://doi.org/10.1016/j.cels.2017.11.010
Please cite this article in press as: Lucarelli et al., Resolving the Combinatorial Complexity of Smad Protein Complex Formation and Its Link to Gene
Expression, Cell Systems (2017), https://doi.org/10.1016/j.cels.2017.11.010Experimental Validation of the Model-Predicted Smad
Complexes
To experimentally validate the model-predicted Smad com-
plexes, we combined sequential IP experiments using lysates
of Hepa1-6 cells with detection by quantitative IB. To confirm
the presence of the model-predicted ppSmad2:ppSmad3:
ppSmad3 complex, we examined a TGF-b-dependent, but
Smad4-independent, interaction of Smad2 with Smad3. We
depleted Smad4 by three repetitive IP experiments from lysates
of Hepa1-6 cells that had been treated with TGF-b or were left
unstimulated. Depletion of Smad4 from the lysate was confirmed
by IB, showing that the Smad4 signal was reduced to back-
ground. The Smad4-depleted lysates were exposed to Smad3
IP, and co-precipitated Smad2 was detected by quantitative
IB. Even in the absence of Smad4, Smad2 associates with
Smad3, but only in lysates of TGF-b-stimulated cells in which
most of Smad2 and Smad3 are doubly phosphorylated (Fig-
ure 3A), thereby supporting the model-predicted ppSmad2:
ppSmad3:ppSmad3 complex. Analogous experiments were
performed to validate the ppSmad2:Smad4:Smad4 complex.
Smad3 was depleted from lysates of TGF-b-stimulated or unsti-
mulated Hepa1-6 cells, again reducing the Smad3 signal to
background levels. The Smad3-depleted lysates were subjected
to Smad4 IP, and the analysis of Smad2 by IB showed the TGF-
b-dependent interaction of Smad2 with Smad4 (Figure 3B),
providing experimental evidence for the ppSmad2:Smad4:
Smad4 complex.
To verify the ppSmad2:ppSmad3:Smad4 complex, we immu-
noprecipitated Smad3 from lysates of Hepa1-6 cells, which were
stimulated with TGF-b or were left untreated. Immunoprecipi-
tated proteins bound to the beads were dissociated by the addi-
tion of an excess of the Smad3 blocking peptide. The resulting
supernatants were used for Smad4 IP, and the detection of
Smad2 by IB confirmed the coIP of Smad2 (Figure 3C). Since
only doubly phosphorylated Smad2 and Smad3 engage in com-
plex formation (Figure 1D), these results verify the TGF-b-depen-
dent formation of a trimeric complex between ppSmad2,
ppSmad3, and Smad4.
Model-Based Link of Smad Complexes with Gene
Expression Dynamics
The impact of individual trimeric Smad transcription factor
complexes on the expression dynamics of specific genes is un-
known. To establish time-resolved expression profiles of TGF-bFigure 3. Experimental Evidence for the Predicted Smad Complexes a
The (A) ppSmad2:ppSmad3:ppSmad3, (B) ppSmad2:Smad4:Smad4, and (C) pp
lated with 1 ng/mL TGF-b for 60 min, or unstimulated, lysed, and subjected to IP
(A) Lysates were depleted of Smad4 by three sequential IPs and used for Sma
Experiments were performed in biological triplicates and means and SD are sho
(B) Lysates were depleted of Smad3 by three sequential IPs and used for Sma
Experiments were performed in biological triplicates and means and SD are sho
(C) Lysates were used for Smad3 IP and proteins were dissociated from beads. T
detected by IB. IPs were confirmed by IB. Experiments were performed in biolog
(D) Microarray-based gene expression analysis of Hepa1-6 cells treated (red) or
divided into 12 groups by k-means clustering. Continuous lines, estimated dynam
(E) Representative TGF-b target genes in each cluster were linked to the reduced p
could have an activating (green) or an inhibitory (red) effect on each target gene
(F) Gene activation dynamics of the 12 target genes were validated by qRT-PCR
area, estimated error.
6 Cell Systems 6, 1–15, January 24, 2018genes, RNA was extracted from TGF-b-treated and untreated
Hepa1-6 cells over time and subjected to microarray analysis.
To define transcripts with similar gene expression kinetics,
k-means clustering was performed. We identified 12 clusters
with distinct dynamic patterns of gene expression, each contain-
ing 20–50 genes (Figure 3D). The transcripts of clusters 1, 2, and
3 showed transient expression kinetics withmaximally increased
gene expression at around 3 hr. Clusters 4, 5, and 8 displayed
sustained dynamics, and clusters 6 and 7 were characterized
by a transient kinetics with a peak at 60 min. In contrast to these
positively regulated clusters, gene expression in clusters 9 to 12
was downregulated by TGF-b.
In each cluster, we selected a representative gene that was
previously linked to TGF-b-induced Smad2/3 signaling. We
selected Ski (Luo et al., 1999) for cluster 1, Skil (SnoN) (Stro-
schein et al., 1999) for cluster 2, Dnmt3a (Domingo-Gonzalez
et al., 2015) for cluster 3, Sox4 (Qin et al., 2009) for cluster 4,
Jun (Koinuma et al., 2009) for cluster 5, Smad7 (Lebrun et al.,
1999) for cluster 6, Klf10/Tieg1 (Dosen-Dahl et al., 2008) for clus-
ter 7, Bmp4 (Greber et al., 2007) for cluster 8, Cxcl15 with its
human ortholog CXCL8/IL8 (Ge et al., 2010) for cluster 9,
Dusp5 (Tao et al., 2016) for cluster 10, Tgfa (Nozato et al.,
2003) for cluster 11, and Pdk4 (Stockert et al., 2011) for cluster
12. To verify that these genes are bona fide TGF-b target genes,
we analyzed the expression of these genes in Hepa1-6 cells
upon stimulation with 1 ng/mL TGF-b in the presence or absence
of the selective TGF-b receptor inhibitor SB-431542. SB-431542
selectively inhibits ALK4, ALK5, and ALK7, and thereby impairs
canonical Smad-mediated TGF-b signaling, whereas non-ca-
nonical TGF-b signaling is not affected (Inman et al., 2002).
Our results demonstrated that SB-431542 reduces the
TGF-b-induced upregulation of the genes of clusters 1 to 8 as
well as the TGF-b-mediated downregulation of the genes of clus-
ters 9 to 12 (Figure S2A).
To quantitatively link the dynamics of TGF-b-induced forma-
tion of Smad complexes to gene expression, we established
an integrative mathematical model that extends our reduced
mathematical model to downstream transcriptional regulation.
Since the specific connection between the considered Smad
complexes and target gene expression was not known, we con-
strained the potential regulatory mechanisms in the integrative
mathematical model as little as possible to allow for positive
and negative regulation of each complex on every target gene,
as well as for a gene-specific turnover (Figure 3E).nd Identification of Distinct Clusters of TGF-b-Regulated Genes
Smad2:ppSmad3:Smad4 complexes were examined in Hepa1-6 cells stimu-
and IB.
d3 IP, which was analyzed first by a Smad2 IB and second by a Smad3 IB.
wn.
d4 IP, which was analyzed first by a Smad2 IB and second by a Smad4 IB.
wn.
he supernatants were subjected to Smad4 IP and the associated Smad2 was
ical triplicates and means and SD are shown.
untreated (gray) with 1 ng/mL TGF-b for up to 10 hr was performed (n = 2) and
ics; dashed lines, cluster average.
athwaymodel, establishing an integrative mathematical model. Each complex
with a gene-specific turnover rate.
. Dots, experimental data (n = 3); continuous lines, model simulations; shaded
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the 12 clusters in Hepa1-6 cells (Figure 3F). The integrativemath-
ematical model was able to describe the expression dynamics of
the 12 representative TGF-b target genes and captured up- and
downregulated as well as transient and sustained gene expres-
sion. The model feature that facilitated the description of
transient or sustained gene expression was a gene-specific
mRNA turnover parameter. We calculated the gene-specific
half-life based on this parameter (Figure S2B). The model
predicted a fast turnover for Jun, Smad7, Klf10, and Bmp4
(half-life < 10 min), an intermediate turnover for Skil, Dusp5,
and Pdk4 (half-life between 10 and 100min), and a slow turnover
for the five remaining genes (half-life >100 min). These model-
predicted values showed good agreement (Figure S2D) with
the mRNA half-life experimentally determined by the addition
of Actinomycin D (Figure S2C).
These results indicate that knowledge on the TGF-b-induced
dynamics of the ppSmad2:ppSmad3:ppSmad3, ppSmad2:
Smad4:Smad4, and ppSmad2:ppSmad3:Smad4 complexes in
Hepa1-6 cells is sufficient to link complex formation to gene
expression.
Modulation of TGF-b-Induced Gene Expression by
Changing the Abundance of the Smad Molecules
The analysis of transcription factor binding sites in the promoter
region of the selected Smad target genes revealed that most of
the target genes contained experimentally validated (Figure 4A,
dashed lines) or expert-curated (Figure 4A, solid lines) transcrip-
tion factor binding sites for at least one of the considered Smad
proteins. For Dusp5 and Pdk4, no transcription factor binding
site for Smad2, Smad3, or Smad4 was reported, indicating indi-
rect regulation.
To elucidate in Hepa1-6 cells the impact of the identified
trimeric Smad complexes on the dynamics of TGF-b-induced
gene expression, we perturbed the system with target-specific
small interfering RNA (siRNA) against Smad3 and Smad4 and
measured the knockdown efficiency for Smad3 and Smad4
by quantitative IB (Figures 4B and S3A). Possibly due to the
high expression level of Smad2 in Hepa1-6 cells, only a mar-
ginal knockdown effect could be achieved for Smad2. To
assess in silico the potential impact of the knockdown of
Smad proteins on the TGF-b-induced formation of the three
Smad complexes, we adjusted in our mathematical model the
initial amounts of Smad3 and Smad4 according to the experi-
mentally measured knockdown efficiency (Figures 4B and
S3A) and performed model simulations to predict the timeFigure 4. Influence of Smad Protein Abundance on the Dynamics of Sm
(A) Analysis of the connection between Smad2 (red), Smad3 (green), Smad4 (blue
System (GePS). Dashed lines, experimentally validated; solid lines, expert-cura
chevrons, phosphatases; stars, co-factors; arrows, activation; diamonds, Smad
(B) Smad3 protein was downregulated using two different concentrations of targe
were performed in biological triplicates and means and SD are shown.
(C) Model simulations of the dynamics of complex abundance after Smad3 knoc
(D) TGF-b-induced gene expression after Smad3 knockdown in Hepa1-6 cells det
means and SD are shown.
(E) Overexpression (OE) of FLAG-tagged Smad2, Smad3, and Smad4 proteins in
(F) Model simulations of the dynamics of complexes upon overexpression of diff
(G) Analysis of TGF-b-induced expression of the selected target genes in Smad-o
SE resulting from scaling of the experimental data by a mixed effects alignment
8 Cell Systems 6, 1–15, January 24, 2018courses of the formation of the three Smad complexes (Figures
4C and S3B). The model predictions suggested that knock-
down of Smad3 had a strong negative impact on the formation
of the ppSmad2:ppSmad3:ppSmad3 and of the ppSmad2:
ppSmad3:Smad4 complex in a dose-dependent manner of
the siRNA, but only a minor effect on the formation of the
ppSmad2:Smad4:Smad4 complex. A similar effect was
observed in response to the knockdown of Smad4, which re-
sulted in a negative effect on the ppSmad2:ppSmad3:Smad4
and the ppSmad2:Smad4:Smad4 complexes, and only minor
effects were observed on the formation of the ppSmad2:
ppSmad3:ppSmad3 complex.
The experimental results shown in Figure 4D revealed that
Smad3 knockdown altered the expression of all target genes.
Positively regulated Smad target genes were suppressed
(e.g., Ski, Skil, Klf10, and Sox4), whereas the expression of
target genes that are repressed by TGF-b stimulation were up-
regulated upon Smad3 knockdown (e.g., Cxcl15, Dusp5, and
Bmp4) (Figure 4D). Comparable effects were observed upon
Smad4 knockdown (Figure S3C), confirming the dependency
of the expression of the 12 selected target genes on Smad
signaling.
To examine the specific impact on the identified trimeric
Smad complexes, we established Hepa1-6 cells overexpress-
ing Flag-tagged Smad2, Smad3, or Smad4, and measured
the total amounts of Smad proteins by quantitative IB (Fig-
ure 4E). A 2-fold increase of Smad2, a 14-fold increase of
Smad3, and a 3-fold increase in the total amount of Smad4
compared with wild-type Hepa1-6 cells were obtained. We
observed that overexpression of one of the Smad proteins
had no major impact on the expression levels of the other two
Smad proteins.
We performed model simulations by adjusting our mathemat-
ical model to the measured overexpression levels to predict the
time courses of the formation of the three Smad complexes (Fig-
ure 4F). Themodel predictions suggested that overexpression of
Smad3 affects the formation of the ppSmad2:ppSmad3:
ppSmad3 and of the ppSmad2:ppSmad3:Smad4 complexes,
while it negatively affects the dynamics of the ppSmad2:Smad4:
Smad4 complex. The model predicted a positive influence
of Smad4 overexpression on the formation of the ppSmad2:
Smad4:Smad4 complex and, to a lesser extent, on the dynamics
of the ppSmad2:ppSmad3:Smad4 complex. On the contrary,
themodel predicted that Smad2 overexpression had little impact
on Smad complex formation. These insights suggest that alter-
ations in the total amount of Smad proteins, in particular ofad Complexes and TGF-b-Induced Gene Expression
), and the 12 selected TGF-b target genes (yellow) by the Genomatix Pathway
ted connections; rounded rectangles, proteins; right chevrons, kinases; left
binding sites.
t siRNA. Lysates of Hepa1-6 were subjected to Smad3 IP and IB. Experiments
kdown. Continuous lines, model simulations; WT, Hepa1-6 wild-type.
ermined by qRT-PCR. Experiments were performed in biological triplicates and
Hepa1-6 cells analyzed by IB.
erent Smad molecules.
verexpressing Hepa1-6 cells by qRT-PCR (n = 3). The error bars represent the
model.
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Figure 5. Mathematical Model-Based Determination of the Impact of Single Smad Complexes on Gene Expression
Prediction of the influence of the single Smad complexes on TGF-b-induced gene expression. Left panel: regulation relative to gene expression at time point
0 min. Green, positive regulation; red, negative regulation; black, marginal impact. Uncertainties of the predictions are visualized by the thickness of the lines.
Right panel: normalized area under the curve of the trajectories (log2), with median and SD. The color code of both panels was normalized for each gene
individually.
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vant complexes are formed.
The time course experiments (Figure 4G, data points) showed
that Smad2 overexpression positively influenced the TGF-
b-mediated induction of Ski, Skil, Dnmt3a, and Sox4. Smad3
overexpression increased the expression of Klf10 and Dnmt3a
at earlier time points, whereas the expression of Sox4 and
Jun was affected at later time points and the expression of
Ski, Skil, Smad7, and Bmp4 was altered during the entire obser-
vation period. Conversely, the TGF-b-induced downregulation
of Cxcl15, Dusp5, Tgfa, and Pdk4 expression was augmented
by Smad3 overexpression. Smad4 overexpression resulted in
an increased upregulation of Klf10 expression and an
augmented repression of Cxcl15 and Dusp5. Our mathematical
model adjusted to the observed overexpression levels of the
Smad2, Smad3, and Smad4 was able to quantitatively describe
the majority of the observed gene expression profiles (Fig-
ure 4G, solid lines). For Dnmt3a, Jun, Klf10, and Cxcl15, the
model trajectories were not able to describe the experimental
data, which might be due to the absence of interactions be-
tween the identified Smad complexes or with co-factors in
our mathematical model.
In sum, the mathematical model was capable of correctly
quantifying the connection between Smad2, Smad3, and
Smad4 levels, the formation of Smad complexes, and the
expression dynamics of the majority of the representative
TGF-b target genes. Since upon overexpression or knockdown
of Smad proteins the dynamics of themajority of genes remained
in the same cluster (Figure S3D), we concluded that, while the
TGF-b-induced expression dynamics is a property of eachgene, the dynamics can be modulated by a change in the abun-
dance of Smad pathway components.
Model-Based Analysis of the Contribution of the
Individual Smad Complexes to TGF-b-Induced Gene
Expression
To quantify the influence of each Smad complex on TGF-
b-induced gene expression, we used our mathematical model
to predict the expression profiles of the TGF-b-induced genes
in the presence of only one of the three Smad complexes
(Figure 5, left panel). We utilized the area under the curve of
the model-predicted gene expression profiles as a quantitative
measure for the extent of gene activation represented by a heat-
map (Figure 5, right panel). In our mathematical model, the rela-
tive influence of each Smad complex on the extent of gene
expression is determined by the activation and inhibition param-
eters multiplied by the complex concentrations and further
modulated by the turnover rates (Figure S4A). To analyze which
activation and inhibition parameter contributed most to the
expression dynamics of the respective gene, we performed a
sensitivity analysis (Figure S4B). These model-based studies
suggested that the ppSmad2:ppSmad3:ppSmad3 complex pri-
marily has a positive influence on the expression of Jun, and a
weakly positive impact on Smad7 which is due to a negligible in-
hibition parameter. The activation parameters of ppSmad2:
ppSmad3:ppSmad3 for Ski, Dnmt3a, Sox4, Klf10, Cxcl15,
Dusp5, Tgfa, and Pdk4 are estimated as zero. On the contrary,
the model predicted that the ppSmad2:Smad4:Smad4 complex
induces the expression of Ski, Skil, Sox4, Jun, and Smad7, and
represses Cxcl15, Dusp5, Tgfa, and Pdk4. For Smad7, theCell Systems 6, 1–15, January 24, 2018 9
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Figure 6. Conservation of Connection of Smad Complexes and TGF-b-Induced Target Genes in Primary Hepatocytes and Hepatoma Cells
(A) Smad protein abundance in primary mouse hepatocytes, HepG2 cells, and primary human hepatocytes determined by mass spectrometry and IB. Error bars
represent SEM (n = 4).
(B) Model simulations of TGF-b-induced gene expression in primary mouse hepatocytes, HepG2 cells, and primary human hepatocytes. Smad2, Smad3, and
Smad4 protein abundance was incorporated in the model. Conserved model parameters linking the three Smad complexes to gene expression were assumed
and cell type-specific TGF-b signaling dynamics were estimated based on the qRT-PCR data (dots, n = 3). Continuous lines, model simulations; shaded area,
estimated error.
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was in agreement with zero. Our mathematical model indicated
that the ppSmad2:ppSmad3:Smad4 complex has the strongest
activation parameter for 7 out of the 12 genes and also the
largest inhibitory parameter for Dusp5 and Pdk4.
In summary, the integrative mathematical model enabled
us to dissect the individual contribution of the three
Smad complexes to TGF-b-induced target gene expression.
While expression of most target genes was positively
influenced by the ppSmad2:ppSmad3:Smad4 complex,
Dusp5 and Pdk4 were transcriptionally repressed by this com-
plex. Possibly the ppSmad2:ppSmad3:Smad4 complex is an
activating transcription factor that exerts its downregulating
function by inducing a transcriptional repressor.10 Cell Systems 6, 1–15, January 24, 2018Protein Abundance-Dependent Model Predictions and
Validation in Different Liver Cell Types
To evaluate Smad complex formation in other liver cells that
potentially harbor different amounts of Smad proteins, we exam-
ined primary mouse hepatocytes, the human hepatoma cell line
HepG2, and primary human hepatocytes.
The abundance of Smad2, Smad3, and Smad4 in these cells
was determined by quantitative IB and quantitative mass spec-
trometry (Figures S5A–S5D). Compared with Hepa1-6 cells (Fig-
ures 1A and 1B), the abundance of Smad2, Smad3, and Smad4
(Table S1) was substantially different in primary mouse hepato-
cytes, HepG2 cells, and primary human hepatocytes (Figure 6A).
Compared with Hepa1-6 cells (Figures 1A and 1B), in primary
mouse hepatocytes the expression of Smad2 was 8-fold lower,
Please cite this article in press as: Lucarelli et al., Resolving the Combinatorial Complexity of Smad Protein Complex Formation and Its Link to Gene
Expression, Cell Systems (2017), https://doi.org/10.1016/j.cels.2017.11.010Smad3 was 3-fold lower, and Smad4 was 5-fold lower. Overall
the abundance of Smad proteins in HepG2 cells was similar to
that in primary mouse hepatocytes, but showing a similar
approximately 10:1 ratio between Smad2 and Smad3 proteins
as in Hepa1-6 cells. Primary human hepatocytes harbored com-
parable amounts of Smad2, Smad3, and Smad4, and the Smad2
concentration was lower by one order of magnitude compared
with HepG2 cells.
To assess the impact of these differences in abundance of
Smad proteins on Smad complex formation, we utilized the
experimentally established cell-type-specific concentration of
Smad2, Smad3, and Smad4 as starting values in our mathemat-
ical model, and predicted the dynamics of the TGF-b-induced
formation of the three Smad complexes for each of the studied
cell types. The model predicted that changes in the total
amounts of Smad2, Smad3, or Smad4 altered the dynamics
of the formation of ppSmad2:ppSmad3:ppSmad3, ppSmad2:
Smad4:Smad4, and ppSmad2:ppSmad3:Smad4 complexes
(Figures S5E–S5G). To experimentally test if these differences
propagate to the expression of Smad target genes, we treated
primary mouse hepatocytes, HepG2 cells, and primary human
hepatocytes with 1 ng/mL TGF-b for up to 10 hr and determined
the dynamics of the expression of the representative Smad
target genes by qRT-PCR analysis (Figure 6B, filled circles,
and Figure S6, open circles). To analyze the obtained data with
our mathematical model, we adjusted the model to the cell
type-specific abundance of Smad proteins. Since we observed
differences in the dynamics of gene activation in the different
cell types, the model parameters of TGF-b receptor activation
and Smad complex formation were newly estimated, while the
model parameters linking the respective Smad complexes to
gene expression were retained. We omitted the mouse-specific
gene Cxcl15 from this analysis. The resulting model simulations
correctly described for each cell type the specific dynamics of
the TGF-b-induced expression of SKI, DNMT3A, SOX4,
SMAD7, KLF10, BMP4, and TGFA (Figure 6B, continuous lines).
DUSP5 was not detectable in primary human hepatocytes and
HepG2 cells, and PDK4 was not detectable in HepG2 cells (Fig-
ure S6). While a transcriptional response of SKIL and JUN to
TGF-b was observed, the cell type-specific expression dy-
namics was not in line with the predicted model trajectories (Fig-
ure S6, continuous lines). The qualitative differences between
the model trajectories and the experimental data for these four
Smad target genes might be explained by cell-type-specific
epigenetic modifications or co-factors that are currently not
considered in our mathematical model.
Our result showed that adjusting our mathematical model to
the measured cell-type-specific abundance of Smad2, Smad3,
and Smad4 was sufficient to predict the dynamics of TGF-
b-induced target gene expression. This supports our hypothesis
that the link between the identified Smad complexes and the
regulation of the expression of themajority of TGF-b target genes
is conserved among the four liver cell types studied.
Gene Expression-Based Prediction and Experimental
Validation of Dysregulation of the Abundance of Smad
Proteins in Hepatocellular Carcinoma
An important role in progression of hepatocellular carcinoma
(HCC) has been attributed to Smad signal transduction (Dzieranet al., 2013). Currently, primarily genome-wide expression
studies are available for patients with HCC. Therefore, we tested
whether a reverse approach can be used to predict the abun-
dance of Smad proteins present in patient samples on the basis
of gene expression data.
We analyzed tumor-free and tumor tissue samples from 30
patients with HCC (Figure 7A, cohort A). By qRT-PCR the
expression of the 12 TGF-b target genes, except for the
mouse-specific gene Cxcl15 and TGFA, which was not detect-
able in human liver tissue, was analyzed. The remaining ten
selected TGF-b target genes showed major alterations in their
expression levels (Figure 7B), with SKI, SKIL, DNMT3A, and
SOX4 being significantly upregulated in tumor samples. Cirrhotic
or non-cirrhotic origin of the tumor samples had no impact on
gene expression, except for BMP4, DNMT3A, and DUSP5,
which were upregulated in cirrhotic compared with non-cirrhotic
tissue.
For each patient, we incorporated the differences in the
expression level of the selected Smad target genes between
the tumor and the tumor-free samples in our mathematical
model and predicted the corresponding alterations of the three
Smad complexes, as well as TGF-b receptor activation required
to achieve the observed expression pattern. Our analysis indi-
cated that no major difference in the formation of the ppSmad2:
Smad4:Smad4 complex occurred in the tumor compared with
the tumor-free samples. However, the model predicted a signif-
icantly higher abundance of the ppSmad2:ppSmad3:ppSmad3
and ppSmad2:ppSmad3:Smad4 complexes in the tumor sam-
ples (Figure 7C).
Because of the model-predicted increase of the Smad com-
plexes in the tumor context, we calculated the total abundance
of Smad2, Smad3, and Smad4 proteins in the tumor-free and
tumor samples on the basis of the predicted amounts of the three
Smad complexes. The mathematical model predicted a signifi-
cant increase in the mean of the sum of all Smad proteins in
the tumor samples (Figures 7D and S7A). By quantitative IB we
determined the abundance of Smad2, Smad3, and Smad4 pro-
teins in the patient samples (Figure S7B). An upregulation of
Smad2, Smad3, and Smad4 (Figure S7C), as well as a significant
increase in the sum of all Smad proteins, was observed in the tu-
mor samples compared with the tumor-free samples (Figure 7E).
We confirmed that in the tissue setting, the TGF-b-induced acti-
vation of the Smad signaling pathway and of Smad target gene
expression are far from saturation (Figure S7D).
The mathematical model predicted that activation of the
TGF-b receptor is significantly elevated in the tumor compared
with the tumor-free samples (Figure 7F). Since it is currently tech-
nically not possible to directly quantify the activation status of the
TGF-b receptor, we used Smad2 phosphorylation as a proxy to
analyze the pathway activation. We collected a new cohort of
fresh patient material (cohort B), and determined Smad2 phos-
phorylation in these samples by quantitative IB (Figure S7E). In
line with the model prediction, a significant increase in Smad2
phosphorylation was observed in the HCC samples (Figure 7G)
and Smad2 protein levels were significantly increased in the
tumor tissue samples (Figure S7F).
In sum, these observations underscore that our reverse
modeling approach is capable of inferring quantitative informa-
tion on the abundance of Smad proteins from gene expressionCell Systems 6, 1–15, January 24, 2018 11
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Figure 7. Prediction of Changes in Smad Abundance Based on Gene Expression in HCC Tissue Samples
(A) Histological images (magnification, 3100) of tumor-free (left) and tumor tissue (right) from a patient with cirrhosis who developed HCC.
(B) Expression of TGF-b target genes in tumor-free and tumor tissue samples determined by qRT-PCR (n = 30).
(C) Model-based prediction of the relative amounts of the Smad complexes based on target gene expression shown in (B) (n = 30).
(D) Prediction of amounts of Smad2, Smad3, and Smad4 based on the abundance of the Smad complexes shown in (C.) (n = 30).
(E) Determination of the amount of Smad2, Smad3, and Smad4 for each patient by quantitative IB. Mean signal of tumor-free samples was adjusted to molecules
per cell measurements in primary human hepatocytes (n = 29).
(F) Prediction of the amount of TGF-b receptor phosphorylation by the mathematical model based on the Smad complexes shown in (C) (n = 30).
(G) Determination of the amount of phosphorylated Smad2 by IB for each patient in an independent cohort B (Figure S7E). Different blots were scaled to each
other relative to the amount of phosphorylated Smad2 in TGF-b-treated HepG2 cells (Figure S7E) (n = 12).
All data are shown relative to the mean of the tumor-free samples. Horizontal lines indicate mean values. *p < 0.05; **p < 0.01; ***p < 0.001; paired t tests.
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Expression, Cell Systems (2017), https://doi.org/10.1016/j.cels.2017.11.010data, and that elevated phosphorylation of Smad2 as well as
elevated expression of Smad2, Smad3, and Smad4 proteins is
characteristic for HCC.
DISCUSSION
In this study, we predicted and provided evidence for the three
most relevant Smad complexes formed in response to TGF-b12 Cell Systems 6, 1–15, January 24, 2018stimulation, and utilized a broadly applicable mathematical
modeling approach to dissect the impact of these complexes
on target gene expression.
Upon TGF-b stimulation only doubly phosphorylated Smad2
and Smad3 engage in complex formation. This notion is in agree-
ment with the crystal structure of the doubly phosphorylated
Smad2 homodimer, which revealed an essential role of both
phosphoserine residues in stabilizing the complex (Wu et al.,
Please cite this article in press as: Lucarelli et al., Resolving the Combinatorial Complexity of Smad Protein Complex Formation and Its Link to Gene
Expression, Cell Systems (2017), https://doi.org/10.1016/j.cels.2017.11.0102001b). Our results showed that only a minor fraction of the
Smad2 and Smad3 molecules present in a cell contribute to
complex formation. Likewise, it was shown that only minor
amounts of Smad3 associate with Smad2 (Wu et al., 2001b).
Out of 84 possible combinations of complexes of non-phos-
phorylated and phosphorylated Smad2, Smad3, and Smad4,
we predicted, by combining quantitative experimental data with
thedevelopmentofamathematicalmodel, the threemost relevant
trimeric Smad complexes in primary hepatocytes and hepatoma
cells: ppSmad2:ppSmad3:ppSmad3, ppSmad2:Smad4:Smad4,
and ppSmad2:ppSmad3:Smad4. These results extend previous
insights obtained by crystallographic studies showing that the
C-terminal domain of Smad4 and the C-terminal domain of phos-
phorylated Smad2 have the capacity to form homotrimers (Wu
etal., 2001a, 2001b).Sedimentationstudiesexaminingphosphor-
ylation-induced Smad complex formation with a pseudo-phos-
phorylated Smad3 showed that Smad3 heterotrimer formation
is favored over homotrimer formation (Chacko et al., 2001). In
line with the ppSmad2:ppSmad3:Smad4 complex that we de-
tected in our study, an in situ proximity ligation assay showed
that TGF-b stimulation induced the formation of complexes con-
sisting of Smad2, Smad3, and Smad4 (Zieba et al., 2012).
Despite chromatin IP and microarray studies (Qin et al., 2009;
Zhang et al., 2011), it was not possible to define the specific
contribution of individual trimeric Smad complexes to gene
expression. By overexpression and knockdown of individual
Smad proteins, and a mathematical model that links the TGF-
b-induced activation of signal transduction to target gene
expression, we dissected the contribution of the identified
Smad complexes to target gene expression and revealed their
positive or negative regulatory effect.
Our analysis indicated that the ppSmad2:ppSmad3:Smad4
complex is the most important complex involved in TGF-
b-induced gene expression with a positive influence on most
of the genes, and that ppSmad2:ppSmad3:Smad4 and
ppSmad2:Smad4:Smad4 complexes repress the expression of
DUSP5 and PDK4. Our transcription factor and simulation
analyses suggested an indirect regulation, possibly mediated
by cell-type-specific co-factors, such as STAT3, GATA4, and
C/EBPb (Qin et al., 2009).
A similar approach was used to investigate erythropoietin-
induced heterodimer formation between Stat5a and Stat5b
(Boehm et al., 2014). In general, our technology combining IP,
quantitative mass spectrometry, and mathematical modeling
with L1 regularization, can be used to quantitatively investigate
protein-protein interactions and thereby add quantitative infor-
mation to protein-protein interactions that were mapped on a
genome-wide scale (Li et al., 2017).
Our systems biology approach enabled us to quantitatively
link the total amount of Smad proteins and Smad-regulated
gene expression in hepatoma cells and in primary hepatocytes.
We provided evidence that alterations in the abundance of Smad
proteins do not change the type but the amount of the three
Smad complexes formed. Our studies show that the link
between the dynamics of Smad complex formation and the
regulation of gene expression is mostly conserved in primary
hepatocytes and hepatoma cells.
Microarray studies of gene expression in HCC are well estab-
lished (Hao et al., 2011). We demonstrated that, with the aid ofour mathematical model, it is possible to predict the expression
of TGF-b-induced genes based on protein data and to use gene
expression data to predict total levels of Smad proteins.
In the presented study, predictions of the mathematical model
indicated that the abundance of Smad2, Smad3, and Smad4, as
well as Smad2 phosphorylation, are increased in HCC tissue,
which was experimentally confirmed in liver samples from HCC
patients. Congruently, a previous study showed that mutations
in the Smad2 and Smad4 genesmight contribute to the develop-
ment of HCC (Yakicier et al., 1999).
As TGF-b can exert multiple functions depending on the
cellular context, it is tempting to speculate that cell-type-specific
abundance of Smad proteins might be key to explain pleiotropic
effects of TGF-b signaling. Therefore, HCC-specific alterations in
the abundance of Smad proteinsmight affect the extent to which
the three complexes are formed, and increase or decrease the
expression of target genes contributing to tumor progression.
Our approach represents a generally applicable framework
that establishes a quantitative link between complex formation
of transcription factors, signaling dynamics, and gene expres-
sion. With this approach it is not only possible to use protein
information to predict the dynamics of gene expression as
commonly practiced, but conversely enables to predict up-
stream protein abundance based on gene expression
dynamics.STAR+METHODS
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EXPERIMENTAL MODEL AND SUBJECT DETAILS
Culture of Cell Lines and Primary Cells
The mouse hepatoma cell line Hepa1-6 (ATCC CRL-1830, female) and the human hepatoma cell line HepG2 (ATCC HB-8065, male)
were cultivated in Dulbecco’s modified Eagle’s Medium (DMEM, Gibco) supplemented with 10% (v/v) fetal bovine serum (FBS, Life
Technologies), 1% 1003 penicillin/streptomycin (Gibco) and 1% 200 mM glutamine (Gibco). Primary human hepatocytes were iso-
lated from macroscopically healthy tissue that remained from resected human liver of three patients with primary or secondary liver
tumors or benign local liver diseases by a two-step EDTA/collagenase perfusion technique (Kegel et al., 2016). Informed consent of
the patients for the use of tissue for research purposes was obtained according to the ethical guidelines of the Charite´ University
Medicine Berlin. Detailed donor anamnesis of the three patients providing primary human hepatocytes is stated in the table below.
Primarymouse hepatocytes were isolated as previously described (Mueller et al., 2015) from 8- to 12-week-oldmale C57BL/6Nmice
(Charles River) housed at the DKFZ animal facility under a constant light/dark cycle, maintained on a standard mouse diet, and
allowed ad libitum access to food and water were used. All animal experiments were approved by the governmental review commit-
tee on animal care of the state Baden-W€urttemberg, Germany (reference number A-24/10). Primary mouse hepatocytes and primary
human hepatocytes were cultivated in phenol red-free Williams E medium (Biochrom) supplemented with 10% (v/v) fetal bovine
serum (FBS, Life Technologies), 0.1 mM dexamethasone, 10 mg/ml insulin (Sigma-Aldrich), 2 mM L-glutamine (Gibco) and 1% (v/v)
penicillin/streptomycin 1003 (Gibco) using collagen I-coated cell dishes (BD Biosciences). 24 hours before the experiment,
1.23106 Hepa1-6 cells and 23106 HepG2 cells, primary mouse and primary human hepatocytes (for IB and qRT-PCR experiments)
and 7.53106 cells (for mass spectrometry experiments) were seeded. 4 hours before the experiment, the different cell types were
washed three times with PBS and kept in growth factor depleted medium supplemented with 1% penicillin/streptomycin (Gibco)
and 1% glutamine (Gibco).Donor anamnesis of the three patients providing primary human hepatocytes
Donor Age (years) Sex BMI Diagnosis
1 58 female 24.7 Liver metastases
2 65 female 22.6 Liver metastases
3 75 male 27 Liver metastasesHepatocellular Carcinoma and Tumor-free Tissue Samples
A first cohort (Cohort A) of samples from liver tumor patients and corresponding tumor-free liver tissue were provided by the Charite´
University Medicine Berlin. Informed consent of the patients for the use of tissue for research purposes was obtained corresponding
to the ethical guidelines of Charite´ University Medicine Berlin. Detailed donor anamnesis is stated in the table below.Donor anamnesis of HCC and tumor-free tissue samples (Cohort A)
Donor Cirrhosis Age (years) Sex
A1 No 71 M
A2 No 74 M
(Continued on next page)
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Donor anamnesis of HCC and tumor-free tissue samples (Cohort A)
Donor Cirrhosis Age (years) Sex
A3 No 58 F
A4 No 78 F
A5 No 58 F
A6 No 68 M
A7 No 66 M
A8 No 87 M
A9 No 76 M
A10 No 76 M
A11 No 71 M
A12 No 61 F
A13 No 61 M
A14 No 73 M
A15 No 65 M
A16 Yes 66 M
A17 Yes 79 M
A18 Yes 56 F
A19 Yes 76 M
A20 Yes 70 F
A21 Yes 67 M
A22 Yes 69 M
A23 Yes 59 M
A24 Yes 76 M
A25 Yes 71 F
A26 Yes 57 F
A27 Yes 71 M
A28 Yes 71 M
A29 Yes 67 M
A30 Yes 63 M
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Expression, Cell Systems (2017), https://doi.org/10.1016/j.cels.2017.11.010A second cohort (Cohort B) of freshly frozen samples from liver tumor patients and corresponding tumor-free liver tissue were pro-
vided by the University Hospital Heidelberg and University of Basel to measure phosphorylation of Smad proteins. Informed consent
of the patients for the use of tissue for research purposes was obtained corresponding to the ethical guidelines of University Hospital
Heidelberg and University of Basel. Detailed donor anamnesis is stated in the table below.Donor anamnesis of HCC and tumor-free tissue samples (Cohort B)
Donor Cirrhosis Age (years) Sex
B1 Yes 66 M
B2 Yes 72 M
B3 No 68 M
B4 No 75 M
B5 No 80 M
B6 Yes 55 W
B7 No 73 M
B8 Yes 64 M
B9 Yes 57 M
B10 No 58 M
B11 No 59 M
B12 No 82 W
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Stimulation, Lysis and SDS-PAGE
Cells were stimulated with 1 ng/ml of TGFb1 (R&D Systems, Cat #240-B-010) for up to 10 hours. For IP, Hepa1-6 cells (23106) were
lysed in total cell lysis buffer (1% NP40, 150 mM NaCl, 20 mM Tris-HCl pH 7.4, 10 mM NaF, 1 mM EDTA pH 8.0, 2 mM ZnCl2 pH 4.0,
1 mM MgCl2, 2 mM Na3VO4, 20% glycerol, 2 mg/ml aprotinin and 200 mg/ml AEBSF). Lysates were rotated for 30 minutes at 4
C,
sonicated and centrifuged for 10 minutes at 20 800 3 g and 4C. The supernatant was subjected to IPs with anti-Smad2/3, anti-
Smad2, anti-Smad3, anti-Smad4 or anti-Flag antibodies (BD-610843, Cell Signaling #5339; #9523; #9515, Rockland 600-401-383
respectively, dilution 1:100), supplemented with Protein A sepharose (GE Healthcare) and recombinant calibrator proteins. The
IPs were rotated overnight at 4C. Immunoprecipitated proteins were separated by SDS-PAGE. Gels used for mass spectrometry
were washed three times with water for 5 minutes and Coomassie stained for 1 hour according to the SimplyBlue SafeStain (Invitro-
gen) instructions. For IB, proteins were transferred to nitrocellulose membranes. IB was performed with anti-pSmad2 (Cell Signaling,
#3108), anti-pSmad3 (Cell Signaling, #9520), anti-Smad4 (Santa Cruz, sc-7966), anti-Smad2/3 antibodies (BD-610843) and anti-Flag
(Rockland 600-401-383) antibodies. Horseradish peroxidase (HRP) conjugated anti-mouse IgG HRP (Dianova 115-035-146), anti-
rabbit IgG HRP (Dianova 111-035-144) and anti-Protein A HRP (GE Healthcare NA9120) secondary antibodies were used for
chemiluminescence detection employing ECL substrate (GE Healthcare). Chemiluminescence was measured with an ImageQuant
LAS 4000 device (GE Healthcare) utilizing a CCD-camera allowing the detection in a broad linear range. Band intensities were quan-
tified using the ImageQuantTL Software (GE Healthcare).
Quantitative Mass Spectrometry
After Smad protein enrichment by IP, the following sample preparation steps were performed: purification per 1D SDS-PAGE, stain-
ing with Coomassie, gel band extraction, destaining, reduction with dithiothreitol (Sigma) and alkylation with iodoacetamide (Sigma).
To analyze the Smad2 and Smad3 degree of phosphorylation and relative protein abundance, both proteins were cut out together
and digested with LysC (Roche Diagnostics). To analyze the relative protein abundance of Smad4, extracts of these gel bands were
additionally subjected to tryptic digestion (Trypsin Sequencing Grade from bovine pancreas, Roche Diagnostics). The digestion
buffer was 100 mM NH4HCO3 in 5% acetonitrile. Following overnight incubation, peptide extraction was performed by transferring
the supernatant to an extra vial and performing three further extraction steps with acetonitrile, 5% formic acid and again acetonitrile.
Samples were concentrated in a Speedvac (Eppendorf) and desalted with C18 Ziptips (Millipore) applying a protocol based on water,
acetonitrile and trifluoroacetic acid. To equalize the recovery of peptides and corresponding phosphopeptides from the LC system,
we added citrate to a final concentration of 20mM to LysC digested samples. Samples were measured by nanoUPLC (nanoAcquity
UPLC, Waters) coupled to an LTQ-Orbitrap XL mass spectrometer (Thermo Scientific). We applied a precolumn setup and acetoni-
trile based gradients (0-40% in < 1 hour). Smad2 and Smad3 protein ratios as well as degrees of phosphorylation were analyzed by
manual peak integration using Thermo Xcalibur Version 3.0.63. Relative protein abundances of Smad2, Smad3 and Smad4 were
analyzed using peptide raw intensities generated by MaxQuant (1.5.0.12).
For pairwise relative Smad2/Smad3 isoform quantification by mass spectrometry, bands from 1D-PAGE were excised, ensuring
that both Smad2 and Smad3 are quantitatively present in one band. Because both isoforms exhibit a high degree of sequence sim-
ilarity, digestion of Smad2 and Smad3 using LysC leads to three categories of peptides. One category consists of identical peptides
for Smad2 and Smad3, the next comprises highly similar peptides that differ only in one or a few amino acids and the third category is
formed by completely different peptides for both isoforms. The isoform abundance for Smad2 and Smad3 can be determined by
comparing the signal intensities within pairs of highly similar peptides. For accurate relative quantification we analyzed two
such pairs. Each pair (Smad2 vs. Smad3) differed in just one amino acid: acSSILPF-pT-PPVVK vs. acSSILPF-pT-PPIVK and
(K)TGRLDELEK vs. (K)TGQLDELEK. All signals detected from these peptides, such as different charge states, threonine phosphor-
ylation (first pair) and deamidation for the second pair as well as versions with and without N-terminal lysine (second pair) were
considered. By applying this strategy, the quantification of the isoform abundances were highly precise (SD < 2%, n = 13, biological
replicates). Isoform ratios calculated from both peptide pairs showed good agreement within 5%. The Smad2 and Smad3 ratio used
for mathematical modeling is the mean of both pairs.
For bulk-based relative Smad4 quantification by mass spectrometry, a lower molecular weight region was additionally excised
from the 1D-PAGE gel. Regarding the amino acid sequence, Smad2 and Smad3 are much more similar to each other than to
Smad4. Therefore, following digestion no highly similar peptides are formed that would be suitable for a pairwise relative quantifica-
tion between Smad4 and Smad2/3. For this reason, the selected quantification strategy relied on the accumulated intensities of all
peptides detectable for each Smad protein. To maximize the number of peptides, tryptic digestion was performed. For relative pro-
tein quantification among all three Smad proteins, the sum of all Smad4 peptide intensities (up to 27 peptides) was compared to the
sum of all Smad2 and Smad3 peptides (up to 16 unique Smad2 peptides, 12 unique Smad3 peptides and 11 common Smad2 and
Smad3 peptides). After that, the highly accurate Smad2 to Smad3 ratio from a corresponding LysC-digested and pairwise relatively
quantified aliquot was used to adjust the accurate ratio among all three Smad proteins.
Relative quantification of Smad2 and Smad3 phosphorylation occupancies was performed by analyzing non-phosphorylated,
singly phosphorylated and doubly phosphorylated C-terminal LysC peptides. The amino acid sequences of the peptides from
both isoforms differ only in exchange of two amino acids (ppSmad2: VLTQMGSPSVR-camC-S-pS-M-pS, ppSmad3:
VLTQMGSPSIR-camC-S-pS-V-pS). Among all detected Smad2 and Smad3 peptides, these C-terminal LysC-fragments showedCell Systems 6, 1–15.e1–e11, January 24, 2018 e4
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For the standard-free quantification method applied, signal intensities of all detectable charge states were taken into account.
Cysteine residues were present as carbamidomethylated (cam) modified residue, because samples were treated with dithiothreitol
and iodoacetamide during the workflow. An additional frequent modification within the analyte peptide is methionine oxidation. This
modification turned out to be phosphorylation-independent. A different methionine oxidation status leads to a retention time shift
(C18 column) of up to several minutes. For Smad2 and Smad3 standard-free phosphorylation status determination of the three
different phospho-forms (non-oxidized, singly oxidized for Smad2 and Smad3 and additionally a doubly oxidized version for
Smad2) showed no significant difference in degrees of phosphorylation, confirming a correct quantification with low random and sys-
tematical errors.
Validation of Complex Formation by Sequential Immunoprecipitations
7.53106 Hepa1-6 cells were stimulated with 1 ng/ml of TGFb for 60minutes or were left untreated. Cells were lysed and processed as
described above. For Smad3 or Smad4 depletion, three sequential IPs were performed with anti-Smad3 (Cell Signaling #9523) or
anti-Smad4 antibodies (Cell Signaling #38454), respectively. The lysates and the depleted supernatants were subjected to an
anti-Smad4 or anti-Smad3 IP, respectively, and IB was performed with an anti-Smad2 (Cell Signaling #5339) antibody, followed
by an anti-Smad4 (Santa Cruz sc-7966) antibody or an anti-Smad3 (Cell Signaling #9523) antibody.
For the validation of the heterotrimeric complex, the lysates were first subjected to an IP with anit-Smad3 (Cell Signaling #9523).
After overnight incubation, bead-bound proteins were dissociated by the addition of a Smad3 blocking peptide (Cell Signaling
#1933S) with a 5-fold excess by weight compared to the antibody. The obtained supernatants were subjected to an IP with an
anti-Smad4 antibody (Cell Signaling #38454). Quantitative IB was performed with an anti-Smad2 antibody (Cell Signaling #5339).
For the detection of the immunoblots chemiluminescence in combination with a CCD camera based device, ImageQuant, was used.
Microarray Analysis of Gene Expression Data
23106 Hepa1-6 cells were stimulated with 1 ng/ml of TGFb for 0, 1, 3, 6 and 10 hours in biological duplicates. As controls, the same
time points were evaluated in duplicates without TGFb treatment. RNA was extracted using the RNeasy Mini Plus Kit (Qiagen) ac-
cording to the manufacturer’s instructions. High-throughput quantification of the gene expression induced by TGFb was performed
using Affymetrix Mouse genome 430 2.0 microarrays according to the manufacturer’s instructions. For preprocessing the R statis-
tical computing environment was used and the robust multiarray average (RMA) algorithm was applied as implemented in the sim-
pleaffy package. The expression data were deposited in the Gene Expression Omnibus (GEO) database under the accession number
GEO: GSE90954.
The selection criterion for the TGFb target genes was a significant (p<0.01) and more than 1.5-fold induction compared to un-
treated controls. For this analysis, a linear model accounting for time and treatment effects was applied and p-values were calculated
based on the t-statistic. Genes that were not constant over time, i.e. showing a maximal regulation of more than 1.5-fold at one point
in time in the untreated controls were discarded from further analyses. The duplicates were averaged and standard errors of the
means were calculated. Since it is not feasible to reliably calculate standard errors from duplicates, the median over all standard
errors was used as uncertainty for further analyses. The dynamics of the induced gene expression as shown in Figure 3D was
then estimated by fitting a five parameter transient function
fðtÞ=Asus

1 e tt1

+Atrans

1 e tt1

e
 tt2 +p0 (Equation 2)
to the time courses for each gene and both treatment conditions.
The first term represents a sustained response with amplitude Asus and time constant t1. The second term accounts for transient
up- or down-regulation with amplitude Atrans with the same time constant t1 for induction and a second time scale t2 for relaxation.
The last parameter p0 is the offset which is specified during fitting primarily by themeasurement at t=0. To prevent overfitting, only the
two mentioned time scales were allowed and the parameters were restricted to reasonable ranges. For both time scales, it was
assumed that they are smaller than two times the whole measurement interval, i.e. t1, t2 < 2 tmax = 20 hours. As lower bounds for
the two time scales, one half of the smallest sampling time interval, i.e. (t2  t1)/2 = 0.5 hours was assumed. Smaller time scales,
i.e. a faster dynamics could not be resolved by the available experimental data and would therefore lead to overfitting of the data
and to large uncertainties of the predicted dynamics. For the amplitudes, the interval [1310-10, 2 Dy] was used as constraint where
Dy denotes the observed range of themeasurements. For the offset, p0˛ [min(y)Dy/2, max(y)] was allowedwheremin(y) andmax(y)
denotes the smallest and the largest observation. All five parameters were estimated by maximum likelihood. Optimization was per-
formed on the logarithmic parameter scale. Next, k-means clustering with k = 12 was performed as implemented in MATLAB using
Euclidean distances. For this purpose, the dynamics estimated for the treated and untreated conditions were merged. Therefore,
genes with a similar dynamics after treatment but with a distinct basal expression could be assigned to different clusters.
For the selection of a representative gene for each cluster, we performed literature mining using the software suites MetaCore
(version 6.31 build 68930) and Ingenuity IPA (build 441680M) to identify potential Smad2-, Smad3-, Smad4- and TGFb-specific target
genes.e5 Cell Systems 6, 1–15.e1–e11, January 24, 2018
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23106 Hepa1-6 cells, HepG2 cells or primary mouse hepatocytes were stimulated with 1 ng/ml TGFb for up to 10 hours in biological
triplicates. Primary human hepatocytes were seeded on collagen-coated 6-well-plates (BD Biosciences) and cultivated as described
for primary mouse hepatocytes (Mueller et al., 2015). Briefly, cells were cultured in full medium at 37C, 5%CO2 in a humidified incu-
bator for 24 hours. For Hepa1-6 and HepG2 cells, medium was then changed to serum-free medium for additional 24 hours. Prior to
TGFb treatment, cells were cultured for 4 hours in serum and dexamethasone-free medium for equilibration. Primary human hepa-
tocytes were then incubated with 1 ng/ml TGFb for 30, 60, 120, 240 and 600 minutes. Cells without TGFb treatment served as nega-
tive control. For the experiments with SB-431542 (Sigma Aldrich, S4317), Hepa1-6 cells were pre-treated for 30 minutes with 5 mM
SB-431542 prior to TGFb stimulation. For samples treated with TGFb alone, as solvent control the same amount of DMSO was
applied. RNA was extracted using the RNeasy Mini Plus Kit (Qiagen) according to the manufacturer’s instructions. Complementary
DNAwas generatedwith the High Capacity cDNAReverse Transcription Kit (Applied Biosystems) and analyzed using the LightCycler
480 with the hydrolysis-based Universal Probe Library (UPL) platform (Roche Diagnostics). Gene-specific primers and UPL probes
are displayed in the table below. Crossing point values were calculated using the second-derivative-maximum method of the Light-
Cycler 480 Basic Software (Roche Applied Science). PCR efficiency correction was performed for each PCR setup individually.
mRNA data was normalized against HPRT.Gene-specific mouse (m) and human (h) primers and UPL probes
Gene Forward primer Reverse primer UPL
mBmp4 gaggagtttccatcacgaaga gctctgccgaggagatca 89
mCxcl15 tgctcaaggctggtccat gacatcgtagctcttgagtgtca 18
mDnmt3a aaacggaaacgggatgagt actgcaattaccttggctttct 75
mDusp5 gatcgaaggcgagagaagc ggaagggaaggatttcaacc 102
mHprt cctcctcagaccgcttttt aacctggttcatcatcgctaa 95
mJun tttgattcaaa agggacccatggaag 12
mKlf10 agccaaccatgctcaacttc ggcttttcagaaattagttccatt 67
mPdk4 cgcttagtgaacactccttcg cttctgggctcttctcatgg 22
mSki gagaaagagacgtccccaca tcaaagctcttgtaggagtagaagc 33
mSkil gacagggaggccgagtatg ccgctcctgtctgagttcat 96
mSmad7 acccccatcaccttagtcg gaaaatccattgggtatctgga 63
mSox4 ctcgctctcctcgtcctct cgtcttcgaactcgtcgtc 63
mTgfa cctggtggtggtctccatt cagtgtttgcggagctga 81
hBMP4 ctgcaaccgttcagaggtc tgctcgggatggcactac 17
hDNMT3A cctgaagcctcaagagcagt tggtctccttctgttctttgc 46
hDUSP5 caaatggatccctgtggaa cccttttccctgacacagtc 5
hHPRT tgaccttgatttattttgcatacc cgagcaagacgttcagtcct 73
hJUN ccaaaggatagtgcgatgttt ctgtccctctccactgcaac 19
hKLF10 tctgaaggcccacacgag acctcctttcacaacctttcc 2
hPDK4 cagtgcaattggttaaaagctg ggtcatctgggcttttctca 31
hSKI gaagcaggaggagaagctcag ccacgcgtaggaactcca 22
hSKIL gaggctgaatatgcaggacag cttgcctatcggcctcag 13
hSMAD7 acccgatggattttctcaaa aggggccagataattcgttc 69
hSOX4 caacgccaactccagctc accgaccttgtctcccttc 25
hTGFA ttgctgccactcagaaacag atctgccacagtccacctg 63Mathematical Model
Development of the mathematical model based on ordinary differential equations (ODEs) and model simulations were performed
using the MATLAB-based modeling environment D2D (www.data2dynamics.org) (Raue et al., 2015). All reactions at the pathway
level were implemented as mass-action kinetics and the impact of the Smad complexes was described by Michaelis-Menten
kinetics. Parameters that were estimated to be very low were set to zero without changing the fit nor the predicted dynamics. Esti-
mated model parameters for the reduced model extended to gene expression are shown in Table S2. The mathematical model and
the data sets are open source and available to the public at www.data2dynamics.org.Cell Systems 6, 1–15.e1–e11, January 24, 2018 e6
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TGFb is binding to the TGFb receptor and is subsequently leading to its activation. In addition the activated receptor can be down-
regulated by degradation (Derynck and Feng, 1997; Itoh and ten Dijke, 2007). The non-phosphorylated Smad2 and Smad3
monomers are susceptible to be double phosphorylated by the active receptor (Massague et al., 2005). The active double phosphos-
phorylated Smad monomers can be inactivated by a two-step dephosphorylation into single phosphorylated and afterwards in non-
phosphorylated Smad monomers. The dissociation of each trimeric Smad complex is dependent on the dephosphorylation of the
double phosphorylated Smad2 and Smad3 in the heterotrimeric Smad complexes or on the dissociation of the homotrimeric
Smad4 complex. The double phosphorylated Smad2/Smad3 and Smad4 are able to form different complexes (Wrana, 2002). The
active Smad complexes activate or inhibit target gene expression (Levy and Hill, 2006; Qin et al., 2009; Zhang et al., 2011).
Reactions of the Comprehensive Mathematical Model
The comprehensive model contains the following reactions:
v1 = ½Rec$Recact$½TGFb (Equation 3)v2 = ½TGFb pRect$Rec degind (Equation 4)v3 = k on 222$½ppS23 (Equation 5)v4 = 3$S dephosphos$½ppS2 ppS2 ppS2 (Equation 6)v5 = k on 333$½ppS33 (Equation 7)v6 = 3$S dephosphos$½ppS3 ppS3 ppS3 (Equation 8)v7 = ½S43$k on 444 (Equation 9)v8 = ½S4 S4 S4$kdiss SS (Equation 10)v9 = ½S2$S phos$½TGFb pRec (Equation 11)v10 =S dephosphos$½ppS2 (Equation 12)v11 =S dephos$½pS2 (Equation 13)v12 = ½S3$S phos$½TGFb pRec (Equation 14)v13 =S dephosphos$½ppS3 (Equation 15)v14 =S dephos$½pS3 (Equation 16)v15 = k on 223$½ppS22$½ppS3 (Equation 17)v16 = 2$S dephosphos$½ppS2 ppS2 ppS3 (Equation 18)v17 =S dephosphos$½ppS2 ppS2 ppS3 (Equation 19)e7 Cell Systems 6, 1–15.e1–e11, January 24, 2018
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Expression, Cell Systems (2017), https://doi.org/10.1016/j.cels.2017.11.010v18 = ½S4$k on 224$½ppS22 (Equation 20)v19 = 2$S dephosphos$½ppS2 ppS2 S4 (Equation 21)v20 = k on 233$½ppS2$½ppS32 (Equation 22)v21 =S dephosphos$½ppS2 ppS3 ppS3 (Equation 23)v22 = 2$S dephosphos$½ppS2 ppS3 ppS3 (Equation 24)v23 = ½S4$k on 334$½ppS32 (Equation 25)v24 = 2$S dephosphos$½ppS3 ppS3 S4 (Equation 26)v25 = ½S42$kon 244$½ppS2 (Equation 27)v26 =S dephosphos$½ppS2 S4 S4 (Equation 28)v27 = ½S42$kon 344$½ppS3 (Equation 29)v28 =S dephosphos$½ppS3 S4 S4 (Equation 30)v29 = ½S4$k on 234$½ppS2 $½ppS3 (Equation 31)v30 =S dephosphos$½ppS2 ppS3 S4 (Equation 32)v31 =S dephosphos$½ppS2 ppS3 S4 (Equation 33)
For the model extension, the genes are linked to the complexes with the following reactions:
v32 =
gene turn+gene act1$½ppS2 ppS3 ppS3+gene act2$½ppS2 S4 S4+ gene act3$½ppS2 ppS3 S4
gene inh1$½ppS2 ppS3 ppS3+gene inh2$½ppS2 S4 S4+gene inh3$½ppS2 ppS3 S4+ 1 (Equation 34)v33 = ½gene$gene turn (Equation 35)
with ‘‘gene’’ representing SKI, SKIL, DNMT3A, SOX4, JUN, SMAD7, KLF10, BMP4, CXCL15, DUSP5, TGFA and PDK4 and
‘‘gene_turn’’ describing the gene-specific and TGFb-independent gene turnover.
ODE System of the Comprehensive Mathematical Model
The ODE system of the comprehensive model determining the time evolution of the dynamical variables is given by:
d½TGFb=dt =  v1 (Equation 36)d½Rec=dt =  v1 (Equation 37)d½TGFb pRecdt = + v1  v2 (Equation 38)Cell Systems 6, 1–15.e1–e11, January 24, 2018 e8
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Expression, Cell Systems (2017), https://doi.org/10.1016/j.cels.2017.11.010d½S2=dt =  v9 + v11 (Equation 39)d½S3=dt =  v12 + v14 (Equation 40)d½S4=dt =  3$v7 + 3$v8  v18 + v19  v23 + v24  2$v25 + 2$v26  2$v27 + 2$v28  v29 + v30 + v31 (Equation 41)d½ppS2 ppS2 ppS2dt = + v3  v4 (Equation 42)d½ppS3 ppS3 ppS3dt = + v5  v6 (Equation 43)d½S4 S4 S4=dt = + v7  v8 (Equation 44)d½pS2=dt = + v4 + v10  v11 + v16 + v19 + v21 + v26 + v30 (Equation 45)d½pS3=dt = + v6 + v13  v14 + v17 + v22 + v24 + v28 + v31 (Equation 46)d½ppS2=dt =  3$v3 + 2$v4 + v9  v10  2$v15 + v16 + 2$v17  2$v18 + v19  v20 + v22  v25  v29 + v31 (Equation 47)d½ppS3=dt =  3$v5 + 2$v6 + v12  v13  v15 + v16  2$v20 + 2$v21 + v22  2$v23 + v24  v27  v29 + v30 (Equation 48)d½ppS2 ppS2 S4dt = + v18  v19 (Equation 49)d½ppS2 ppS2 ppS3dt = + v15  v16  v17 (Equation 50)d½ppS2 ppS3 ppS3dt = + v20  v21  v22 (Equation 51)d½ppS3 ppS3 S4dt = + v23  v24 (Equation 52)d½ppS2 ppS3 S4dt = + v29  v30  v31 (Equation 53)d½ppS3 S4 S4=dt = + v27  v28 (Equation 54)d½ppS2 S4 S4=dt = + v25  v26 (Equation 55)d½gene=dt = + v32  v33 (Equation 56)
with ‘‘gene’’ representing SKI, SKIL, DNMT3A, SOX4, JUN, SMAD7, KLF10, BMP4, CXCL15, DUSP5, TGFA and PDK4. The ODE
systemwas solved by a parallelized implementation of the CVODES algorithm (Hindmarsh et al., 2005). It also supplies the parameter
sensitivities utilized for parameter estimation.
Identification of the Occurring Smad Complex Using L1 Regularization
L1 regularization is a general methodology to establish models with a minimal number of parameters, i.e. to reduce the complexity of
models down to a level which is required to explain the data. In the context of ODE models of signaling pathways, L1 regularization
was applied to determine the cell-type specific parameters (Merkle et al., 2016) and was described in detail in the setting of ODE
models (Steiert et al., 2016).e9 Cell Systems 6, 1–15.e1–e11, January 24, 2018
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2
pen = c
2
data + c
2
l1 which is a sum of a term c
2
data =Si (yi – gi)
2/s2
assessing agreement of the data yi, i=1,.,ndata with the model gi and a second term c
2
l1 = l Sj j qj j penalizing parameters
qj, j=1,.,npara, which are different from zero. Since the penalty terms in c
2
l1 have a non-vanishing gradient ±l for all values unequal
to zero, parameters which improve c2data less than lq are estimated equals to zero.
In our context, L1 regularization is applied to identify the complexes which are required to describe the coIP data. For these com-
plexes, c2pen is optimal for non-vanishing association rates. For complexes which are not required, the penalty c
2
l1 dominates the
data contribution c2data and therefore the association rates are estimated to zero.
Model Prediction and Experimental Validation of mRNA Half-lives
mRNA half-lives were calculated based on the gene-specific turnover parameters, with half-life = ln(2)/turnover. The mRNA turnover
of each gene was classified as fast (half-life < 10 minutes), intermediate (half-life between 10 and 100 minutes) or slow (half-life >
100 minutes). The confidence interval of each gene-specific turnover parameter was determined by the profile likelihood method
(Raue et al., 2009). To experimentally determine mRNA stability, Hepa1-6 cells were cultivated and growth factor depleted as
described above and were stimulated with 1 ng/ml TGFb for 2 hours followed by treatment with 1 mg/ml Actinomycin D to inhibit tran-
scription. Total RNA was extracted at specific time points and was analyzed using qRT-PCR. The mRNA half-life was estimated by
fitting the mRNA expression to a 3-parameter exponential decay function: y = y0+a exp(-b x). mRNA half-lives were calculated as:
half-life=ln(2)/b. Confidence intervals were calculated based on the standard errors of the estimates.
Gradual Knock-down of Smad Proteins
0.5x106 Hepa1-6 cells were cultivated in DMEM (Gibco) supplemented with 10% (v/v) FBS (Life Technologies) and 1%200mMgluta-
mine (Gibco) for 24 hours and siRNA transfection was performed according to the Lipofectamine RNAiMax protocol (Invitrogen,
Cat. #13778-150). SMARTpool siRNA against Smad2 (L-040707-00-0005), Smad3 (L-040706-00-0005) and Smad4 (L-040687-00-
0005) was obtained from Dharmacon. ON-TARGETplus Non-targeting pool (D-001810-10-20) served as siRNA control. After 24
hours, medium was exchanged with fresh medium containing 1% 100x penicillin/streptomycin (Gibco) for another 24 hours. Growth
factor depletion was performed as described before. Hepa1-6 cells were treated with 1 ng/ml TGFb and RNA was harvested at the
indicated time points as described above. Additionally, unstimulated cells were lysed as described above to access the knock-down
efficiency. IP was performed with specific antibodies against Smad2 (Cell Signaling, #5339), Smad3 (Cell Signaling #9523)
and Smad4 (Cell Signaling #38454). Quantitative IB was performed with anti-Smad2 (Cell Signaling #5339), anti-Smad3 (Cell
Signaling #9523) and anti-Smad4 (Cell Signaling #38454) antibodies, respectively. Knock-down efficiency was assessed by immun-
blotting relatively to the impact of control siRNA.
Overexpression of Smad Proteins
Mouse Smad2, -Smad3 and -Smad4 inserts were obtained from total RNA of primary mouse hepatocytes. The RNA was reverse-
transcribed into cDNA. The insert was re-cloned into the retroviral expression vector pMOWS-Flag-MCS using PacI and EcoRI re-
striction sites. Transfection of Phoenix eco packaging cell line was performed by using calcium phosphate precipitation. Transducing
supernatants were generated 24 hours after transfection by passing through a 0.45 mm filter, supplemented with 8 mg/ml polybrene
(Sigma). Stably transduced Hepa1-6 cells were selected in the presence of 1 mg/ml puromycin (Sigma) 24 hours after transduction.
Transcriptional Activity of Smad Complexes
The mathematical model was utilized to assess the gene regulatory impacts of the individual Smad complexes ppSmad2:
ppSmad3:ppSmad3, ppSmad2:Smad4:Smad4 and ppSmad2:ppSmad3:Smad4. For this purpose, the transcriptional activities of
all complexes except a single complex of interest cwere virtually prohibited in themathematical model by setting the respective acti-
vation- and inhibition parameters to zero. For quantitative assessment, the areas under the curves
AUCc;gðpÞ= 1
tmax
Z tmax
t = 0
log2

xgðt;pÞ

xgð0;pÞ dt (Equation 57)
of the log2-ratios of the concentrations xg(t,p) after TGFb stimulation relative to the steady state expression at time point t=0 were
calculated for all genes g, each individual complex, and a given parameter vector p. Negative AUCc,g indicates negative regulation
of the respective Smad complex c on gene g, a positive AUCc,g is obtained for positive regulators. To translate uncertainties in the
estimated parameters p toAUCc,g(p), the analysis was repeated for all statistically valid parameters obtained for the profile likelihood.
Analysis of Hepatocellular Carcinoma Samples
Each liver tissue piece (Cohort A) was cut into 20-30mg pieces and homogenized in total cell lysis buffer for protein analysis or in lysis
buffer RA1 (Macheroy & Nagel) for RNA isolation in a Precellys 24 homogenizer (VWR Life Science). Protein lysates were rotated for
30 minutes at 4C, sonicated and centrifuged for 10 minutes at 20 800 3 g and 4C. Supernatants were subjected to IPs with anti-
Smad2/3 (BD-610843) or anti-Smad4 (Cell Signaling #9515) antibodies and supplemented with Protein A sepharose (GE healthcare
17-0963-03) and 1 ng GST-Smad3 or 1 ng SBP-Smad4 calibrators, respectively. Lysates were rotated overnight at 4C and analyzed
by quantitative IB. Protein signals were determined as described before and normalized against the respective calibrator signal toCell Systems 6, 1–15.e1–e11, January 24, 2018 e10
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the molecules per cell of Smad2, Smad3 and Smad4 in primary human hepatocytes. Accordingly, the relative signal intensities were
translated into molecules per cell values for each sample. RNA was isolated from the homogenized samples according to the man-
ufacturers protocol (Macheroy &Nagel). RNA integrity number (RIN) wasmeasured to assess the quality of the isolated RNA revealing
a RIN value of 7-9 for all samples. Samples were further subjected to qRT-PCR analysis as described above.mRNAdata was normal-
ized against the geometric mean of TBP and UBE2R2.
Phosphorylation of Smad2was detected in human tissue samples fromCohort B. Samples were homogenizedwith a plastic pestle
and were processed as described before. Lysates of tissue samples (1000 mg protein) as well as of reference samples from unstimu-
lated or stimulated (1 ng/ml TGFb for 60 minutes) HepG2 cells (100 mg protein) were subjected to IP experiments with an anti-Smad2
(Cell Signaling #5339) antibody andwere supplemented with Protein A sepharose (GE healthcare 17-0963-03). IPs were rotated over-
night at 4C and were analyzed by quantitative IB. Protein signals were determined as described above and normalized against the
TGFb-stimulated reference sample from the HepG2 cell line.
Prediction of Complexes and Total Amounts
The integrative dynamic model for TGFb-induced Smad complex formation and the subsequent effect on target genes was used to
predict the regulation at the level of the Smad complexes from observed gene expression level in patients suffering from hepatocel-
lular carcinoma. As a first step in this analysis, the steady state concentrations of the genes and the complexes were calculated for
the parameters fitted for Hepa1-6. For this purpose, a receptor activity of 10% relative to the estimated maximal activity after the
treatment of Hepa1-6 with 1 ng/ml TGFb was assumed. Then, the observed fold-changes at the gene expression level for an indi-
vidual patient relative to the average over all tumor-free samples were added to the gene expression level in themathematical model.
Next, three parameters for concentration fold-changes of ppSmad2:ppSmad3:ppSmad3, ppSmad2:Smad4:Smad4 and
ppSmad2:ppSmad3:Smad4 were introduced and estimated for a single patient while keeping all other parameters fixed. For this
step, only the part of the model linking the complexes to the genes was required. Structural identifiability was checked using the pro-
file likelihood approach (Raue et al., 2009). In addition, a weak prior log10 fold N(m,s2) with m=0 and s2=4 was used to decrease the
variability of the estimates in the case of weakly informative expression data. In analogy to the analysis for the Smad complexes, the
observed regulation at the gene expression level was also used to predict regulation at the level of the total Smad concentrations.
Again, the steady states for the gene expression were calculated for the model fitted for Hepa1-6 and by assuming 10% of the
maximal experimentally observed receptor activity for the cell line. Three fold-parameters S2fold, S3fold, S4fold were introduced rep-
resenting the alteration in Smad2, Smad3, and Smad4 abundances. Then, the measured fold-changes for the gene expression in
tumor-free and tumor tissue in individual patients relative to the average over all tumor samples were added to the steady state levels
of the model. For these changes at the gene expression level, the corresponding four parameters were then estimated to predict
altered activation levels of TGFb receptors and fold-changes of Smad2, Smad3, and Smad4.
QUANTIFICATION AND STATISTICAL ANALYSIS
Microarray expression data was considered significantly regulated if p<0.01 as tested by a two-factorial linear model and if they
showed an at least 1.5-fold increase compared to untreated controls. The dynamics of gene expression was estimated based on
amathematical function approximating the trajectories for all genes. Transcripts that were not constant over time (higher fold-change
than 1.5) in the untreated control were discarded and transcripts were considered as significantly regulated if p<0.01 (two-factorial
linear model) and if they showed an at least 1.5-fold increase compared to untreated controls.
qRT-PCR data and predicted Smad complexes from paired tumor-free and tumor tissue (n=29) were expressed as log2 values with
the average of the tumor-free value set to zero. Here, significance was tested by paired two-sided t-tests, with significances defined
as *, p<0.05; **, p<0.01; ***, p<0.001. The predicted and measured sum of Smad2, Smad3 and Smad4 from paired tumor-free and
tumor tissue (n=29) were expressed as molecules/cell with the average of the tumor-free value set to the measured values in primary
human hepatocytes. Significance was tested by paired two-sided t-tests, with significances defined as *, p<0.05; **, p<0.01.
Significance of IB data of Smad2 phosphorylation amounts (n=12) was tested by paired two-sided t-tests, with significances defined
as *, p<0.05; **, p<0.01; ***, p<0.001.
DATA AND SOFTWARE AVAILABILITY
The modeling framework, the mathematical model and the data sets are open source and are available here: http://www.
data2dynamics.org.
The microarray expression data were deposited in the Gene Expression Omnibus (GEO) database under the accession number
GEO: GSE90954: https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE90954.e11 Cell Systems 6, 1–15.e1–e11, January 24, 2018
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Figure S1 (related to Figure 1 and Figure 2): Comparison of Smad antibody specifi-
cities, determination of the total amount of Smad molecules and complex formation
and phosphorylation of Smad molecules in Hepa1-6 cells and fits of the comprehen-
sive mathematical model
3
Figure S1 (Continued) A. Equimolar amounts of recombinantly produced GST- or SBP-tagged
Smad2, Smad3 and Smad4 proteins were mixed and subjected to immunoprecipitations with
antibodies directed against Smad2, Smad3, Smad4 and Smad2/3. Protein ratios of precipitated
proteins were determined by quantitative mass spectrometry. B. Whole cell lysates of 2×106
Hepa1-6 cells were analyzed for endogenous levels of Smad2 and Smad4 by means of dilution
series of added recombinant calibrator proteins SBP-Smad2 and SBP-Smad4, respectively. Protein
levels were determined by immunoprecipitation (IP) and subsequent quantitative immunoblotting
(IB). Data of GST-Smad3 was not used due to the resulting high background of the immunoblot.
Linear regression analysis (solid lines) was performed for recombinant calibrators SBP-Smad2
and SBP-Smad4, respectively. Endogenous protein levels of unstimulated cells (dashed lines)
were calculated by means of the respective regression functions. a.u.: arbitrary units. C. Hepa1-6
cells were treated with 1 ng/ml TGFβ in a time-resolved manner (upper panel) or stimulated
for 60 minutes with different concentrations of TGFβ (lower panel). Whole cell lysates were
subjected to immunoprecipitation with antibodies directed against Smad2, Smad3 and Smad4
and analyzed by quantitative mass spectrometry for the relative protein abundance. Error bars
represent 5% error for mass spectrometry measurements (n=1). D. Hepa1-6 cells were treated with
TGFβ for 60 minutes with different concentrations of TGFβ. Whole cell lysates were subjected to
immunoprecipitation with antibodies directed against Smad2/3 and analyzed by quantitative mass
spectrometry. Data was converted to molecules/cell based on the results depicted in Figure 1.
n: non-phosphorylated; p: single phosphorylated; pp: double phosphorylated. E. Time-resolved
mass spectrometry analysis of the relative protein abundance for Smad proteins and complexes.
Whole cell lysates of Hepa1-6 cells were stimulated with TGFβ for 240 minutes, lysed at indicated
time points, subjected to IP with anti-Smad2 (n=1), anti-Smad3 (n=2) and anti-Smad4 (n=2)
antibodies and analyzed by quantitative mass spectrometry (dots: experimental data, continuous
line: model trajectories; shading: corresponds to 5% error, which is typical for mass spectrometry
experiments). Dose response experiment after 60 minutes stimulation with 0, 0.1 and 1 ng/ml of
TGFβ (Smad2 IP n=2, Smad3 IP n=1, Smad4 IP n=1, Smad2/3 IP n=2).
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1.2 Figure S2
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Figure S2 (related to Figure 3): TGFβ target gene validation and comparison of
model-predicted to experimentally measured gene stability
5
Figure S2 (Continued) A. Hepa1-6 cells were pre-treated with 5µM SB-431542 or DMSO as
control for 30 minutes prior to stimulation with 1 ng/ml of TGFβ. Total RNA was extracted and
analyzed by qRT-PCR for the twelve representative Smad target genes. Experiments were per-
formed in biological triplicates and mean and standard deviations are shown. B. The uncertainty
of each gene-specific turnover parameters was analyzed by the profile likelihood method. X-axes
show the parameter value of the analyzed turnover parameter. Y-axes describe the difference in
likelihood. Black stars denote the value for the best fit. Red dashed lines define the point-wise
confidence interval in likelihood difference, defining the confidence interval of the model-predicted
half-lives. Based on the best fit, the turnover parameters were classified as fast (half-life <
10 minutes), intermediate (half-life between 10 and 100 minutes) or slow (half-life > 100 minutes),
with half-life = ln(2)/turnover. C. Hepa1-6 cells were pre-stimulated with 1 ng/ml of TGFβ for
120 minutes and subsequently treated with 1µg/ml of Actinomycin D to inhibit transcription.
mRNA stability was measured for up to 360 minutes. Total RNA was extracted and analyzed
by qRT-PCR for the twelve representative Smad target genes. mRNA half-lives (black dashed
lines) were estimated by exponential decay functions (black solid lines). Confidence intervals are
given in squared brackets. D. Model-predicted half-lives determined in (A) are compared to ex-
perimentally measured half-lives as indicated in (B). Error bars represent respective confidence
intervals.
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Figure S3 (related to Figure 4): TGFβ-induced gene expression in Hepa1-6 cells upon
knockdown of Smad4 and cluster stability of TGFβ target genes
7
Figure S3 (Continued) A. Smad4 and Smad2 proteins were down-regulated in a gradual way by
using two different concentration of target siRNA. Whole cell lysates of Hepa1-6 were subjected
to immunoprecipitations with anti-Smad4 and anti-Smad2 antibodies, respectively. Signals were
quantified by an ImageQuant device utilizing a CCD-camera and Smad expression was accessed
relative to the scrambled siRNA control. Experiments were performed in biological triplicates and
mean and standard deviations are shown. B. Simulations with the integrative mathematical model
for the time-resolved complex abundance after a gradual knock-down of Smad4 in presence of
1 ng/ml of TGFβ were performed (continuous lines: predicted model trajectories). WT: Hepa1-6
wild type. C. TGFβ-induced gene expression after Smad4 knock-down in Hepa1-6 cells was
determined for the selected twelve TGFβ target genes by qRT-PCR. Experiments were performed
in biological triplicates and mean and standard deviations are shown. WT: Hepa1-6 wild type.
D. Hierarchical clustering was performed for averaged, log2 transformed gene expression data of
1 ng/ml of TGFβ-stimulated Hepa1-6 cells. Gene expression was measured under the following
nine conditions: Hepa1-6 wild-type cells, Hepa1-6 cells overexpressing Smad2, Smad3 or Smad4,
Hepa1-6 cells treated with 5 nM or 15 nM Smad3 siRNA, with 2.5 nM or 5 nM Smad4 siRNA or
with 20 nM scrambled siRNA.
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Figure S4 (related to Figure 5): Sensitivity analysis of activation and deactivation
parameters contributing to target gene expression
A. TGFβ target genes were linked to the reduced pathway model, establishing an integrative
mathematical model. The induction of target gene expression by the respective Smad complex
was modeled by an activating (Act1, Act2 Act3; green) and by an inhibitory (Inh1, Inh2, Inh3;
red) parameter. Turn: Gene-specific turnover rate. B. Sensitivity analysis of the activating
and inhibitory parameters on target gene expression. Parameter values were increased (red) or
decreased (blue) by two-fold compared to the parameter value estimated for the best fit of the
reduced model shown in Figure 2C, and the relative change of the area under the curve of the
respective gene was calculated as a measure of the impact of parameter variation on target gene
expression.
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Figure S5 (related to Figure 6): Determination of the total amount of Smad molecules
in primary mouse hepatocytes, the HepG2 cell line and primary human hepatocytes
and model predictions for the impact of Smad amounts on the dynamics of the
complexes
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Figure S5 (Continued) Whole cell lysates of primary mouse hepatocytes (A.) and HepG2 cells
(B.) were analyzed for endogenous levels of Smad2 and Smad4 by means of dilution series of
added recombinant calibrator proteins SBP-Smad2 and SBP-Smad4, respectively. Protein le-
vels were determined by immunoprecipitation (IP) and subsequent quantitative immunoblotting
(IB). Data of GST-Smad3 was not used due to the resulting high background of the immu-
noblot. Linear regression analysis (solid lines) was performed for the recombinant calibrators
SBP-Smad2 and SBP-Smad4. Endogenous protein levels of unstimulated cells (dashed lines)
were calculated by means of the respective regression functions. a.u.: arbitrary units. C. Whole
cell lysates of unstimulated primary human hepatocytes from two patients were analyzed for
endogenous levels of Smad2 and Smad4 by immunoprecipitation (IP) and subsequent quanti-
tative immunoblotting (IB). Lysates of HepG2 cells were used as comparison to calculate the
total amount of Smad molecules. D. Immunoprecipitations of whole cell lysates with antibodies
directed against Smad2/3 were performed and Smad isoform ratios were analyzed by quantita-
tive mass spectrometry (assuming 5% measurement error) to determine Smad3 protein abun-
dance (n=3). Error bars represent standard error of the mean. Model simulations indicating
the effect of increasing (green) and decreasing (red) Smad2 (E.), Smad3 (F.) and Smad4 (G.)
protein levels relative to the amount in Hepa1-6 cells (black) on the complexes formation of
ppSmad:ppSmad3:ppSmad3, ppSmad2:Smad4:Smad4 and ppSmad2:ppSmad3:Smad4. Simulati-
ons have been performed for 1 ng/ml TGFβ stimulation. E. Increasing amounts of Smad2 enhance
the abundance of ppSmad2:Smad4:Smad4 and ppSmad2:ppSmad3:Smad4 and renders the forma-
tion of ppSmad2:Smad4:Smad4 from transient to sustained. F. Increasing amounts of Smad3
enhance the production of the ppSmad2:ppSmad3:ppSmad3 complex but at the same time reduce
the formation of the ppSmad2:Smad4:Smad4 and ppSmad2:ppSmad3:Smad4 complexes. G. In-
creasing amounts of Smad4 enhance formation of ppSmad2:Smad4:Smad4; but this increase at the
same time reduces the production of ppSmad2:ppSmad3:ppSmad3 and ppSmad2:ppSmad3:Smad4.
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1.6 Figure S6
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Figure S6 (related to Figure 6): Model predictions for gene expression revealed in-
direct TGFβ target genes in primary mouse hepatocytes, HepG2 cells and primary
human hepatocytes.
Continuous lines represent the trajectories and shaded area the estimated error of model simu-
lations based on the Smad protein abundance (Figure 6A) and the qRT-PCR data (Figure 6B)
in primary mouse hepatocytes, HepG2 cells and primary human hepatocytes. Empty circles re-
present experimental data points (n=3) that were not used for parameter estimation. See STAR
Methods for donor anamnesis of primary human hepatocytes. n/d: not detected.
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1.7 Figure S7
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Figure S7 (related to Figure 7): Smad protein abundance and phosphorylation in
hepatocellular carcinoma and corresponding non-tumor tissue samples
13
Figure S7 (Continued) A. The relative amount of Smad2, Smad3, Smad4 was predicted by the
integrative mathematical model based on the Smad complex formation. Mean signal (crossbar)
of tumor-free samples was adjusted to molecules per cell measurements in primary human he-
patocytes (Fig. 6) (n=30). ∗, p < 0.05; ∗∗, p < 0.01; paired t-test. B. Proteins were extracted
from hepatocellular carcinoma (T) and corresponding tumor-free (F) tissue samples (cohort A).
Immunoprecipitation (IP) and quantitative immunblotting (IB) was performed. Calibrator for
the Smad proteins were used to normalize the signals, thus making them comparable between
different blots. Patient samples (P) 1 to 15 correspond to non-cirrhotic livers, patient samples
16 to 30 to cirrhotic livers. See STAR Methods for donor anamnesis of tissue samples (n=29).
C. The amount of Smad2, Smad3 and Smad4 was measured by quantitative immunoblotting for
each patient. Mean signal (crossbar) of tumor-free samples was adjusted to molecules per cell
measurements in primary human hepatocytes (Fig. 6A) (n=29). ∗, p < 0.05; paired t-test. D.
For the Smad pathway activity in liver tissue, a constant level of active TGFβ receptors at a
level of 10% compared to the stimulation setting for Hepa1-6 was assumed. Saturation in the
pathway and at the promoter levels was checked in this setup by ten-fold decreasing and incre-
asing the number of active receptors. E. Proteins were extracted from hepatocellular carcinoma
(T) and corresponding tumor-free (F) tissue samples (cohort B). Immunoprecipitation (IP) and
quantitative immunblotting (IB) was performed. Data was normalized to a sample of stimulaF.
The relative amount of Smad2 was measured by quantitative immunoblotting for each patient.
Values are expressed relative to the mean signal (crossbar) of the tumor-free samples (n=12).
∗∗∗, p < 0.001; paired t-test. a.u.: arbitrary units.
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2 Supplemental Tables
2.1 Table S1
Table S1 (related to Figure 6): Smad abundances in different cell types
cell type Smad2 Smad3 Smad4
(molecules/cell) (molecules/cell) (molecules/cell)
Hepa1-6 cells 825 × 103 83 × 103 402 × 103
primary mouse hepatocytes 100 × 103 30 × 103 85 × 103
HepG2 cells 100 × 103 12.5 × 103 90 × 103
primary human hepatocytes 12 × 103 15 × 103 28 × 103
2.2 Table S2
Table S2 (related to STAR methods): Estimated model parameters for the reduced
model extended to gene expression
For the reduced mathematical model, the seven kon parameters of the irrelevant complex para-
meter were set to 0. In total 108 parameters are estimated from the experimental data. The best
fit yields a value of the objective function −2 log(L) = 213.832 for a total of 1755 data points.
The model parameters were estimated by maximum likelihood estimation. The parameter name
prefix sd indicates the estimated error of a observable. θˆ indicates the estimated value of the
parameters. θmin and θmax indicate the upper and lower bounds for the parameters. The log-
column indicates if the value of a parameter was log-transformed. The fitted-column indicates
if the parameter value was estimated (1) or was fixed (0). Parameters highlighted in grey color
indicate parameters that were not estimated, while red color indicate parameter values close to
their boundaries. 24 parameters representing activation or inhibition strengths were estimated to
the presumed lower bound (1 × 10−5) indicating vanishing effects of the respective complexes on
certain genes. Since these parameters did not couple to others, they could be set to zero without
changing the fit nor the predicted dynamics.
name θmin θˆ θmax log non-log θˆ estimated
1 Rec act -5 -2.2220 +3 1 +6.00 · 10−03 1
2 S2tot -5 +2.1547 +3 1 +1.43 · 10+02 1
3 S3tot -5 +1.2111 +3 1 +1.63 · 10+01 1
4 S4tot -5 +1.8264 +3 1 +6.71 · 10+01 1
5 S dephos -5 -0.5387 +3 1 +2.89 · 10−01 1
6 S dephosphos -5 -1.3055 +3 1 +4.95 · 10−02 1
7 S phos -5 -0.4202 +3 1 +3.80 · 10−01 1
8 Ski act3 -5 -1.8502 +3 1 +1.41 · 10−02 1
9 Ski act2 -5 -3.0936 +3 1 +8.06 · 10−04 1
10 Ski act1 -5 -5.0000 +3 1 +1.00 · 10−05 1
11 Ski inh3 -5 -5.0000 +3 1 +1.00 · 10−05 1
12 Ski inh2 -5 -1.3314 +3 1 +4.66 · 10−02 1
13 Ski inh1 -5 -1.5721 +3 1 +2.68 · 10−02 1
14 Ski turn -5 -2.3412 +3 1 +4.56 · 10−03 1
15 Skil act3 -5 -0.3347 +3 1 +4.63 · 10−01 1
16 Skil act2 -5 -1.1277 +3 1 +7.45 · 10−02 1
17 Skil act1 -5 -1.5129 +3 1 +3.07 · 10−02 1
15
name θmin θˆ θmax log non-log θˆ estimated
18 Skil inh3 -5 -5.0000 +3 1 +1.00 · 10−05 1
19 Skil inh2 -5 -0.1233 +3 1 +7.53 · 10−01 1
20 Skil inh1 -5 -0.3871 +3 1 +4.10 · 10−01 1
21 Skil turn -5 -1.9489 +3 1 +1.12 · 10−02 1
22 Dnmt3a act3 -5 -2.1455 +3 1 +7.15 · 10−03 1
23 Dnmt3a act2 -5 -5.0000 +3 1 +1.00 · 10−05 1
24 Dnmt3a act1 -5 -5.0000 +3 1 +1.00 · 10−05 1
25 Dnmt3a inh3 -5 -5.0000 +3 1 +1.00 · 10−05 1
26 Dnmt3a inh2 -5 -1.7140 +3 1 +1.93 · 10−02 1
27 Dnmt3a inh1 -5 -1.4416 +3 1 +3.62 · 10−02 1
28 Dnmt3a turn -5 -2.4191 +3 1 +3.81 · 10−03 1
29 Sox4 act3 -5 -1.9521 +3 1 +1.12 · 10−02 1
30 Sox4 act2 -5 -3.5660 +3 1 +2.72 · 10−04 1
31 Sox4 act1 -5 -5.0000 +3 1 +1.00 · 10−05 1
32 Sox4 inh3 -5 -5.0000 +3 1 +1.00 · 10−05 1
33 Sox4 inh2 -5 -1.0590 +3 1 +8.73 · 10−02 1
34 Sox4 inh1 -5 -0.9873 +3 1 +1.03 · 10−01 1
35 Sox4 turn -5 -3.0958 +3 1 +8.02 · 10−04 1
36 Jun act3 -5 -5.0000 +3 1 +1.00 · 10−05 1
37 Jun act2 -5 +0.0083 +3 1 +1.02 · 10+00 1
38 Jun act1 -5 +0.7776 +3 1 +5.99 · 10+00 1
39 Jun inh3 -5 +0.9139 +3 1 +8.20 · 10+00 1
40 Jun inh2 -5 +0.1635 +3 1 +1.46 · 10+00 1
41 Jun inh1 -5 +0.9893 +3 1 +9.76 · 10+00 1
42 Jun turn -5 -0.9166 +3 1 +1.21 · 10−01 1
43 Smad7 act3 -5 +2.9992 +3 1 +9.98 · 10+02 1
44 Smad7 act2 -5 -0.6740 +3 1 +2.12 · 10−01 1
45 Smad7 act1 -5 +1.3198 +3 1 +2.09 · 10+01 1
46 Smad7 inh3 -5 +0.5644 +3 1 +3.67 · 10+00 1
47 Smad7 inh2 -5 -5.0000 +3 1 +1.00 · 10−05 1
48 Smad7 inh1 -5 -5.0000 +3 1 +1.00 · 10−05 1
49 Smad7 turn -5 +1.5612 +3 1 +3.64 · 10+01 1
50 Klf10 act3 -5 +2.9998 +3 1 +1.00 · 10+03 1
51 Klf10 act2 -5 +1.9569 +3 1 +9.05 · 10+01 1
52 Klf10 act1 -5 -5.0000 +3 1 +1.00 · 10−05 1
53 Klf10 inh3 -5 -5.0000 +3 1 +1.00 · 10−05 1
54 Klf10 inh2 -5 -1.7483 +3 1 +1.79 · 10−02 1
55 Klf10 inh1 -5 -3.1199 +3 1 +7.59 · 10−04 1
56 Klf10 turn -5 +2.6754 +3 1 +4.74 · 10+02 1
57 Bmp4 act3 -5 -5.0000 +3 1 +1.00 · 10−05 1
58 Bmp4 act2 -5 +1.9563 +3 1 +9.04 · 10+01 1
59 Bmp4 act1 -5 +3.0000 +3 1 +1.00 · 10+03 1
60 Bmp4 inh3 -5 +3.0000 +3 1 +1.00 · 10+03 1
61 Bmp4 inh2 -5 +1.2875 +3 1 +1.94 · 10+01 1
62 Bmp4 inh1 -5 +2.3394 +3 1 +2.18 · 10+02 1
63 Bmp4 turn -5 -0.0037 +3 1 +9.91 · 10−01 1
64 Cxcl15 act3 -5 +0.9658 +3 1 +9.24 · 10+00 1
65 Cxcl15 act2 -5 -5.0000 +3 1 +1.00 · 10−05 1
66 Cxcl15 act1 -5 -5.0000 +3 1 +1.00 · 10−05 1
67 Cxcl15 inh3 -5 -5.0000 +3 1 +1.00 · 10−05 1
68 Cxcl15 inh2 -5 +2.5045 +3 1 +3.20 · 10+02 1
69 Cxcl15 inh1 -5 +3.0000 +3 1 +1.00 · 10+03 1
70 Cxcl15 turn -5 -2.4845 +3 1 +3.28 · 10−03 1
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name θmin θˆ θmax log non-log θˆ estimated
71 Dusp5 act3 -5 -5.0000 +3 1 +1.00 · 10−05 1
72 Dusp5 act2 -5 -5.0000 +3 1 +1.00 · 10−05 1
73 Dusp5 act1 -5 -5.0000 +3 1 +1.00 · 10−05 1
74 Dusp5 inh3 -5 -0.3265 +3 1 +4.72 · 10−01 1
75 Dusp5 inh2 -5 -1.9383 +3 1 +1.15 · 10−02 1
76 Dusp5 inh1 -5 -1.9620 +3 1 +1.09 · 10−02 1
77 Dusp5 turn -5 -1.8497 +3 1 +1.41 · 10−02 1
78 Tgfa act3 -5 -1.8941 +3 1 +1.28 · 10−02 1
79 Tgfa act2 -5 -3.5337 +3 1 +2.93 · 10−04 1
80 Tgfa act1 -5 -5.0000 +3 1 +1.00 · 10−05 1
81 Tgfa inh3 -5 -5.0000 +3 1 +1.00 · 10−05 1
82 Tgfa inh2 -5 +0.1420 +3 1 +1.39 · 10+00 1
83 Tgfa inh1 -5 +0.3965 +3 1 +2.49 · 10+00 1
84 Tgfa turn -5 -2.4431 +3 1 +3.60 · 10−03 1
85 Pdk4 act3 -5 -5.0000 +3 1 +1.00 · 10−05 1
86 Pdk4 act2 -5 -3.3134 +3 1 +4.86 · 10−04 1
87 Pdk4 act1 -5 -5.0000 +3 1 +1.00 · 10−05 1
88 Pdk4 inh3 -5 +0.1104 +3 1 +1.29 · 10+00 1
89 Pdk4 inh2 -5 -1.1915 +3 1 +6.43 · 10−02 1
90 Pdk4 inh1 -5 -0.8540 +3 1 +1.40 · 10−01 1
91 Pdk4 turn -5 -1.8241 +3 1 +1.50 · 10−02 1
92 init Rec -5 +0.2639 +3 1 +1.84 · 10+00 1
93 k on 223 +0 +0.0000 +3 0 +0.00 · 10+00 0
94 k on 224 +0 +0.0000 +3 0 +0.00 · 10+00 0
95 k on 233 -8 -0.8326 +3 1 +1.47 · 10−01 1
96 k on 234 -8 -3.3944 +3 1 +4.03 · 10−04 1
97 k on 244 -8 -5.0641 +3 1 +8.63 · 10−06 1
98 k on 334 +0 +0.0000 +3 0 +0.00 · 10+00 0
99 k on 344 +0 +0.0000 +3 0 +0.00 · 10+00 0
100 k on 222 +0 +0.0000 +3 0 +0.00 · 10+00 0
101 k on 333 +0 +0.0000 +3 0 +0.00 · 10+00 0
102 k on 444 +0 +0.0000 +3 0 +0.00 · 10+00 0
103 kdiss SS +0 +0.0000 +3 0 +0.00 · 10+00 0
104 pRec degind -5 -1.3968 +3 1 +4.01 · 10−02 1
105 sd Bmp4 -5 -0.8506 +3 1 +1.41 · 10−01 1
106 sd Cxcl15 -5 -0.8712 +3 1 +1.35 · 10−01 1
107 sd Dnmt3a -5 -1.0139 +3 1 +9.68 · 10−02 1
108 sd Dusp5 -5 -0.9758 +3 1 +1.06 · 10−01 1
109 sd Jun -5 -0.7831 +3 1 +1.65 · 10−01 1
110 sd Klf10 -5 -0.9290 +3 1 +1.18 · 10−01 1
111 sd Pdk4 -5 -1.1309 +3 1 +7.40 · 10−02 1
112 sd Ski -5 -0.9903 +3 1 +1.02 · 10−01 1
113 sd Skil -5 -0.7570 +3 1 +1.75 · 10−01 1
114 sd Smad7 -5 -1.1523 +3 1 +7.04 · 10−02 1
115 sd Sox4 -5 -0.8985 +3 1 +1.26 · 10−01 1
116 sd Tgfa -5 -1.1122 +3 1 +7.72 · 10−02 1
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